var title_f21_49_22288="Upper airway size analysis";
var content_f21_49_22288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper airway size analysis in obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 722px; background-image: url(data:image/gif;base64,R0lGODlhTwHSAvcAAP///39/fwAAAL+/vz8/P+/v79/f38/Pz7/M5Z+fnz9msv8/P/+/vwAzmS8vL29vb19fXx8fH3+ZzA8PD6+vr4+Pj09PT/9/f/8AAP/v7/8PD/8fH/8vL/9fX/+fnw8/n//Pz+/y+P+vr/9PTx9Mpd/l8v/f3/9vb/+Pj19/v5+y2K+/3z9MZk9yuL8AAM/Y6x8mMy8zOQAmcl9ymQ8ZLH9fXy9ZrC9MhT8AAH8ZTI+ZrH8fHx8zWT8PD79fX19mcgAZTH8AAAAMJn8/P58fHz8vL9+fn+8DCT9fn4+l0gAshc8PD8+fnx8jKT8fH58TOb+Pj5+sxd8GE+8zOQAvj78/P3+SuD9ZjM/S2E9SWd9fX49mkt8fH8+vr89PT2+MxZ8zWY+fvx85bC9Wop+Pj298lT9JXB8shQ8cNr8fH9+1wi88Vh9Gkm9PT79PTx88lQ8pXN/i6M+/v59SeW8cVp9vb98mM88ZLN9/f29fX982Ql8fX7/F0u8vL98vL69fX78vL09iqI+SmV9shS9Pj+9CSY8PD59ymb8PD9+/v2+JvM8vL6+Pj8+ovD9Wgt9PT99mcu8fH6+yuF95rB8AAB8/f+/Pz38PD29/n48fH88/P99vb59fX59/f+8AAL/I27/CyN/Pz29Mha+vz++Pjw8TGU9vr88AAI9/f5+CqH9vbwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABPAdICAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNqLVDgAYACAAwAeABWq9mzMwc4iECgAoAKBCI4GIC2LsQJAizYxfhAAAGwBQgI8Lq3cEIKAhKXNRxxAFzHbwe0pcu4skALAiAIcGs54oGCnztXLpD3gAAHogUSWM06teuEFfwGSBy684DbAyBAeM27YIQJqx1k7h0gQO/jpneHFTCBuPHjvA0MECvw9uLUxROyJkAYuve92RHe/3YxoPb382bDJ8SAvn3QAAkKJghAuSsBCxQUqkfI3r1/nQkIRgBBiAnwnGAPCEfZQfsd1N9/ENaUoF8DFTABXsYZIEAEACQwHEINGvRghCTGNACFlzkwm3EnDthiQiEWNGKJNLL0IgCIVaAZBNJReONAxRVHwHPr1WikjSjOllhiAWjIoYfKARnkkAvNeOSVIiWgWQRNAmmgaoMpCCOR/GFp5kgPbFdbgPF9lSZ++pHp4Jl08hQjQVbWqadMdw6U556AttSnQH8GaihKgwJQ6KGMjpTooo1G6tGjklZKEqWWZroRbrnJKaKmoGK0HZdVhmoqRpieqqpEqa7qakOtvv8qK4ieyjjrrbSWiuuuUurKa53wDUSBBfeFZh+cY/r6K5YBoggAAQ4INwFYCIqZq0KQImTAdeYtG9UAxVXQbUITDigQdQo62eGHDNaKZ0RdPTAfAI4RMECb3jpFQQRLJkbAuAf9KJCF074oML24QeCunxJ5GAFdXflFXb5MxUYABYAlwC/ABR2sWXwGO6saa6RiCy+0BOx2wFoE4EuxUsEaBMGCCf1YgHBtqgtlsiZHZEACB4jFlVcTv5zUdQUhbZCWG3bJL1stPxumADQXFKvRhlVQAVgPcIxQmqx9tl3Ux+bHc5FYV6bkBAfYK+jChKZdWVsFQDDBXG8rK7ddFrT/qVnViMKt6N6GQXaZ15cKni3hhl7NeF3gBlm0SY4/bpaH/QKeuN6WnzUbBbgpDRKnCnPeuVYGTDB5SaMqTtF8kp9e1M2Zq1Q5Q/PtUEOXsg81mwNh2+56RQsw0HtRHr50e0PFH09U6goXt/rmPVPUvPNCnVh7SsszdD32QBXA6QCiOzq89caDb1XMABwAQcrGvmn2tWijrz5QBgi2pOZLCzjwhQG4ELWmxj8AdG8h37ufnU4TPIaUSyA7+5jO2GWQAyokgQoEkAAmcqMVGdBAITNXu0z3EAxmMCcpi11DOvilFYXwbGUiXvpOqJMC7c8hN4qgABIwwSiNbDUlO4gI/ziAgRGAwH401MnnQtcQpnFpWwAUoNQmVDXSuYsBGvBABi6ggQxMxIRJpEnqpqcQsK3mM+6D38DkFyeEdOAEA+HADCECxjDKRHs35J67OoCCgdQRgXO0I03apibhIUQEGjiiB7r4xUAKkjF94iIGNsAEJD5SJhwrABlB0ifWWCsif7yk7SCANAPg7SR9uo0MwOXDEjpSlCyhwIUeADoKbGmTH0lUAywSSliixACaWdIEAlC+kOhyIKd0pS9pchvEieSYAqkAh+j4ymVepXUL2eVAnGmQXiLEPJq05lCsmE35FLCb1azZY+IjrwcQU5xEgaawIlDMgngzaX0hgFgGwP8vl8ETKPIcyNYcck+CrIwt8Xkf8Or5TxAVUo/lNIj4mJdOhAwtLGE5AA8bGhEbJuacnBScNgsiS4YCoKAc7UgAuNSkaRlSISMtCLIuWNGUcrJlf6EaRdJogfqwEYYHialEUGpTjSSAbUvi5kFSN0y8iKVaOqUfQoRKkNTVk6hFxYj4CsAmipyInoIJ2obW1UqCBNQgFigrQbD6svH55ABBUypCgjlMevlIZFYTqUK4QlPwrUYGq+EJ7S4mAJMuNVqaYdsLCUJOmDKElAhhq9GoihMPEQsAUY2IB/vSpLHujCDYdOxCLKCXg0j2ZZS9SQDslVOQioc5AdQpVAt41oP/cDWyNX1cam1y1AA4QDOGPciwUubT+8xvhKJlCPnQSZEgse9Wu7WJcBLTncBF1IGlXWtuQVSDHTx3VtGtCVcDcFzrJnchgUHaaQHAgAVI5KJgMYBGg1sX8eFGrgYJ70zaht9c6lWGFWmvRNTCFrcQK1r0PUvbYkAD7lBEvzLRkGuf+V+HBEi7AXavRPIJlgPwq7yuQYACLALhmJjSAio0b0JKPLAIzG+9Am7MY9zSTrIcR8Qk9gkeP/rSFfsMwxSJsUTAiUvL4LgiLH6JfZkI0fM6BJgCgbGGA3XkB/8kctIzSWN9DK8IuEXKh6ryRJLsEtNsjySh5bJn6AJmQ4lZ/yJkFtQEdHPUBGuktg4BwQgwwAERBHnKgHpzROLMktXqCLMTVmmFI7KBDpgAkds1iJBR4rLpYEXQECH0SqRpmk+ictEPYQAHBoKCDkxk0iVxpwN6ejMLPCC7CemWebYFkf52BNMP0bRKDNCkHa0EzwwR9UA8MIJTA9okgnnOV3FZr3tFpi0HiNe8lLvOleDaIbrWCrAXkoEsAgAEG/CAsfW4avLd59V7zadY8jcYsDhswhHTp7VHzMEBrDLRdtn2QsCNAQwQAd8EQbVJKl3kg0YtQHKJNsrUahCD+7Mh0mHyQxbc4Oo6ZDVCCOxVVpoYgayMORbP63UvYmv2HhsnF/9d91j4+rOgNSTlDSMADGDwL3gNQAc3KI+VsdKXnrbpw5h5eK+cXBEHhHwhAn+yc4UuFQlIoCLXbki2U4Jl3sFrQ/NB42lwlBeg5lcjbYtI0iEegO5+lypOhzq9d86THWcWIicCTmJ65CK8mhXUGMH32B2y96Y/nSJRZ8jUUbkZicOdQpxdrJSEhHeHmLHmy0l034N98qmAiwUssDpEAj/yGm7wIqThUF+2xpy3DCavjO/8xAdwAx0sF4KCG8jkkV55qVw+80VGCOeJjhPopTgifRGOA7h2mgttUt8MUQACDgJXyltk9k9JO+DXPmYd9+vtHQ3AQAVCAe3jEvkLUT7/g+hJ++fXfiERv03ubSL9iexezTtZsnV6PFWLiP8gtCx/hicSICc4IWpB0X4S8X715xPyZ2cZ0SclkAINoAIVcX8IgTEJAX0TeH4McQEXQBQCGBEEGFQ+kTpn9mkJQQINUIIOOBEQeBC/VYHmVxEYOBHyV3JjQxEbuHnUB2c+YTEpozr0RxAIUIIleIMPkYISBVkHQYEIgYQG8YJDRgBF0AMO1hgDQB4ARxA1+BAd+HU9sVoB4BUCUHKo4i4lAIQNkAIUQYQReIQW6HwUwYTjVhGLkxBX6BBZWBCDRzlzMQF9UYUJuDASUIJKUAJnuHzoNwEPp4SStoYK4YYSgYi2/1IRc9gQdTgQP0iIO9E2pnQaCBiGClECCMB0DYGGzBdyjhhwipgQjCh2p1g/ExGJDDGJAPCHJfh3PbFVvxZ7YWEBCCiK32QepSh7q3gQqQgRvxg3kEiLAyiEDvEBQPgBPTEstARrI5FmC/E+EsGLwsU2wNiCbZiBf2YRcYgQrrgQsMiMJeiMl+gvGgKG9XYbpfNk12iJTVQbxWhyLuiNb0gR4XgQ46gQWWgAFjABstgAyIgTK0UBA4J9JZEoJDV8QyiPDiGB9ViMwxhqwTgnx6h2T1YBBmAAA4UAOQCRBjkX9vKFPYheK+gQ2JgQEOAAltAB4bZ/3SiT+mgR/ZgQnP8HFplRNCaAASbQE05yIdPUZA/BVyopkg1RA57QARfQaN84k09Zkxk5fQohTbVyAhiwABgARzyhMafBjhfBkAehG6GIlAzRAaYGAN12RI14kQVRkXznlo9IgwVpg8LlFqBzhIkEACagAZFWF2IpUQ4AigOxkgnxPZJFkfjYluBok3WJhdQnFtLEGQhxAVwJAHDJJ86VZRXxPm3ycXrYRhVRZIaJECdQbN+mAV2QjxKRmWwolXRJESXQAh/ggABZWAkRThZwCVM2An2UE9fHY83FJAIBdDvkdRCRMgpRmgeRARzAAR2gAV4wAZRpkfdIk5oVAEEQmAZxkwdBgib4Fkr/Y2lB1z6hoAEjwADR6UU5gRd6+Hu1dhpf0mlcJ413ZxGBsUnMeUgXcERccTPb95qtuZiq2FwBAATcORAZEJ0bQKCSmANScARPEAhVlQD5YQEREB/dYgIdsACOFn/SlBlgCQCr5kGKV0G4qFwIsZ84pIvhpH8T4ZowWn1fNAImIGoOqhAUQARyZAIjMAW85hWrRZhD8XEpehCxkSZ+cRt3JUIC4VxUghFzdhAsChFHZZ8FoZjYiYMS0ZPsKQKVJx2fIR0U8ACS4QJ+ppYYQAb55xTNMpibCEFAhHWk0RxJinpcmBEHgKVVChETBR+io6VRSaO11gUaIHsuQCGzMSAB/+IVATJM4MIFM4QB7PkUiQEcDTSczxF8xoecFFEA5dWnEoGQboE0HsABlRoRMqoQv5gBKJADKJCqthUAeiFLBACdaskBOSoQDzABVXMCqAoAHTBqURGcCgl39CEs3ieaGZE6LiOqn7qTarkAGsAB3jagW+oQzrkAF7AAxHoudNE2G3QAD1CdIKCVWylcdCEuBrGg/bYAbHkmCcoQB0Am0EoRHqlJXhCsiCSrDbGqLCgRKDBlG/AHpHQAwMEVryeOjwkBGQoq89oQGiUQ92oRA7AEaXpSfzkQACuMG6ABHeCvNRMAWoCPJ1AFAdoQJaAAZuhxDvsVphKx9GqIAFCxFv8xAt6YARsAAgnAkQ+BlhOxSCLAoZU3H2IhJtyBB8GqsxlLh0CoAAlQAPW6focis/R6ACVAAo9JEgyAARcApu6lJfEBLfEBOpMDbhuQtvFKUBmrAZ0gFnhBFyi2T93UaE4ZES1AhmZAtY1ita/4tCvBACPArf5qaYY2Fm7joQJxAhp2AMtltAZUcwQwARSwABm7AXWgcg4hAjmwtg+Rt0D4ArLitwsBuiUoupeYl5TqJ26xGuyUrBVAAWLhchcQrCewAWwXEYMAuKN7pHhLhqjrE34pECBwqBGBlXzmubnmp3YjECUgASeoKlt2a0AoAw7At08aJETqEVzkAR7QoCv/UWJcAUzYKynU2BHP64Bt+hAB8AM8cHYk4QELsADiFr4NUQE0my+k2xi+C4tIEV2giiN8GCr7W2spKYnKWBW75WFOSjEF7Kezi8BnQVk8NFFp88CeUVfkmMBUQVVrMcCugsGeEXv+exQjBRkjuioi/F4Pg5McHBUh8IcSEAIas72SElv5C5pHN3QsUWe698JQwYAlmAJG6Squ1hcCIBbGCYorXBESWBAlTBRkeIeAIhjlsXWIgaXZGxMYOjlRvBK8pr0QAUxKAIQksCvqcqII446+myVI88Uc5FxVyGvuC79LhSMQEAbM+AErgCumpI1qfL4vAQG6KBCwGMbFYcOM/xUAmJesyegQBTAbExMCCBACuIKwEWAspXenUgUTBdA3hgzECUHH76vIBeGdB5GTYvEA5Rsq12ccnMqDnXxHmECCKWDJ7ifKcri1ElyVoWk0m0kZ3eeznvoSoEAFQMjLGzyVuXwYCBNGTawRPwiEY0CVsWnNBWEAbBGnjBPNGREC5tgAYrAtAdBf/ovKBvFmCUAXpnw83pwRK2DLlgxMHPIzuXfOyrzMA+GwIHw67ywSA2ABqDEAT5zOusywFBHPZSgJu9HKzvPPJaEWLmIes1mb7mcDNmCWCgHOQAgHbaw+EI0oEaAyBgCeDRgRYwiEgihRYKF+BlTO0xyEvjS9Sv/xAGhAhiM2H+ycrDrdIck6CWQoBglFnSR6nO+THxVAHxw9i74kyEmR0kPs0zs91VINAFZAhlYwu3Kl0LcMTyHdErJIAisNEQog01kFEV/dEp5YES8QvGftEGn91lUR13I9FXRd11Fx13gNFI5rUnq914I1XcfJrIBdGElapwvx14WNQrJ1rDy82HZhxVJzTooN2TYh2ZJdEMa62Zzd2Z792aAd2qI92qRd2qZ92qid2sbazz1x2KVH2BLhNhzUwI1B28nZz34rGRZBurI9EX7b209BO4lBpLwNwrpdEcdNEcCdncht2+z70aCF29CtGqz9VgtbzA2x3A+R3LNtEdr//dzNvdvTTd0V8dvVzRTF7VXOjUPrnd3SHd7lPd7P8t7Kfd5LkQDtbBBds1M77BDkahH7/Tr5bVD93UQDThABzn8HzqspbNkO/uAQHuESPuEUXuEWfuEYnuEavuEcbhA7xnAdXhUnMhf8Yt9OkX4uXdgjzk8u1RkBQjLyLUo7BnmvUdmP8yKW5RyL/SKxocVqE+OXtGOZrOOFLX/QYeMhPhNInuQxseRM3lz+1NNuYlyw/eQ70SxOWiAHQkDYbeUSIhwiRDBf0kNd7uXM5CwCbaJNWuZmfkcokiM7Qnd25aQvDkRA3uYRnSSvTOYDgeLviOc54URW50FT5GkiB+g5//F4awKAZVPliA4VTv7oC3nnkr4TkV7pFIbpUnHpmu5fnQ7plP7pHRMuDY5DUBrqoo4j/NIvNB4SVRelqY4RFiOBXLUxKhbruy10M3PruP6pucnrvT5kobFRhYbqnV4gf/HdlGPsmp4yFBAtyj7pwV4RF/MVhg4r+DJcFhA/VM7m034QCUAYFgJwWD4Q0CItA0RF3v7tHPFA5yIQ6eJZFHTo7O5VzkW1B0Mw4rPmA/HqzP7pmJNHyoVXHzPnBt/vp17vwwk687dCzkI7OSPvIM7pGj5GESHoSrwhrlvojv3SCg+Dgt3xCF5IYxMfjb7uH+8lwHNGJ5nyC5E8LkHxGf/ue5wJ7C6vEG5n4mj9750uf9e97DcPUDyv6ewm8CIY9LDCQCxPEv6O9E30eSjR9AZBa9uE9ClU80dfIQ8gLyxSbSnvUSIfUkuzIRCjbi6/RA3P64EBPCrDMgv+6BafN9kMNELTFRiV8jnf8k4PGmNT6sy995yEL2kEAdw+U8gF+A1nUUVW7l8RRS41Wyj/8QFghH2eTF8D5hA0HBIk8ZGv8LKkh7V0SwNvLh7kQvx++IifzcF0qe80+k/aQiB0+mFB06nfMTq33SiiQzzE+QNR53Ex9EiP8QQTQI/P5bNc+xWh6O3zPoS/Rt1+/MgPEzIf/R4P7veO9FXn0GHpLrn/szvaX+lmZvRAf5gbm+oBRGctbvN+VP6ibmi7EfaeTv5Oz2nyqfPgLf9Iz2vANO8hARAGBgwcACEAAIQJFS5goNDhQ4gRJU6kWNHiRYwZNW7k2NHjR5AKDxwwcCDkxQQEVBKIcFAiw5MxZc6kWdPmTZwUCzgQQICCgAI5IwZwGRGmUKRJlS5l2tRhAgEWCAAQMMAp0YlHnW7l2tXr14QBCAwgUKDq1aIQtYJl29btW44JJgRwAAEo2qwN4e7l23cvTwECHmzF+lKvX8SJFSctkCAABa6FjR5eXNnyZY4HCJgEeQACAQtWARR4ABqyRMlqKWNm3do1QgNnPxqYMHeC/wADAAgI5ikaYuqHa18PJ47YgAMLRAPk3jhAQIQCu0k+BwAVAuq0wVcX594drPPAgX1rtCtgLgDnU9Njl5iBgwfv8eVzLUBwYNCNx+uaP7B+fcIBlBMru4Q80GABDUbYiDOECmBuPggjjKg+gvDTKAABDnogw9giqE6A6wAUkAACATABAxAAcA8FjCogqwKTHkjggQAslPDG+WgLTzaNnLPtrN0e6I29hxhYICERjrzIgCCDGiACARLAccr5KuiJAAgmeFAjCqSCQDTSTJsIOIQY2CChCzrAKKUIHDDpMwfKonJO7gYcTAAGlyITIQ5GYOACFDHK7YECgiopgS3pVP+UNboGmGDD8ZTaEwA5qnABESgqWHRTTjU7TgAHbJS0RABKoyEGlkLkdFU66xN11IkUQAAAA0hl9VZcZ5oUIVkTGilXYIM9aVcAekWIggnyFHZZZiki1liEAlC2WWqXDVA5EmOd1aHTqvV2LyZ3jPSma4nKViJoE6rrW3bdwjBOlaZF6tltFTLAgnbz/Qqqr+idUF5996JwIIAlGniAgvfCUrlEk/IXImQTDpgtzWKggYDBMqr44owV+0lcvNCt96HHIqpVOSkn7goBBTxi+TIMKagw5IjShahhWgOoYYcAUlZ5q5c7Croy2nDW09ZiR4ZoXYiM/NmroTeKWjHwwhv/F6MAoBQAoQN4enRMpG1+yADomlbyaaBbFlrtyjRbabOONgwtZSi7jJLImpWWqGGnMxoUv0NfRZuiqTMqfEqzInDMpANABeAnfIcKW2+IHFW27xZZcsAqqRwIdXCMDr9I9L7cXkniiHzcDTf/esIbIrEjotEhzC+KTjCu6wY9dLal7p3qHXnMaL0NA2h9qoRSWqklbTOysXaLXCTAxVJnJHR3i0ivSHvEEnCgo8RLFaACsyYAwMqOabXPoOYxgkBV6C/K00HsR//d8Psr++lqizbk6XP/1cZoAHjYkrRUprPVDyncmwgD32K626BOIhQIAPkSQsEKDJCAk/NI/BR4/xMHRiSEbaka7mgGO8pRhDYH8AAHMvBBipRrORwZ4UNqCKwCZkQVp9gABzSQIhimLgAsYMEMfeey/CHmYIITSg4x0gEFAcADZwqiRCQgASRm0TKOAllTnHgRrWwAiFV8yBW1SMMk9gVDNCKKBm/yRYssAD4qwsALyVhGLK7tjItxDhNhJTKOiEADHhABBxYhwdkk4ABBKdRgDFUqP7aFfgkxQCQhYkY9ZtIyBIAX3LzIwUCOYAEX+InParKTOOFrAA6IwPTOpzn+sUVGNGqkjJCGxz1q5IZfsVIXhSIQgrAPkCH5FU5+EgHObEhOt0vfXp50tw9FIJaXzCMac5kYK/9ZsibKUwnzhnkSCsiJJqSZJXoqMBZNSY96NjGlQBRiSonAqSzRiZOqLIJJa2pyMbRJwMw+2b6TFOB9N6mkSBxSMAMokpGkGQ2tDpAAJtIIOVbBmFQK0CUHEMuhiIKNIt3oEHweUZ/A8+XRACqTi7oFlaBBDytd2bnPQWQ3LiGbbDCEPKSEFCMbw1g+iSYgIzIFjiBx1C2Zcsxk9iQoB9Ddb+gSGgBY4AEWHYAFMmrUk+jUdgPQwQ0Q5lN9DbUz3XrIwT4KEnLOyJzorN4DrheRdo4HnjnRKu+u2ZcZmS5eJ3xI7GLCpGlppgg9IMBcbVJQXylkkoqpq/0yQwCL9TT/MWIpofD+mDeOnIwoho2Wh8w2sQARMaj440h9uvrVTX0mZV0zTzMdItaJ1OoHPOjZRIJCVgSCdohFPKsN07i93/JFhr39TWBcUjcLQNOpEikBCaopUhVGwJ4A8CC7Gpu94DYwu2+p7DQn0jieHAS8j4vK6xSCgAakd7sQCSFDFVLdb123Io0QxV39giEX3acjyMHQQY5n3oS0IL3pfQFYLeKm3KpMvu3hQA9/aODE/CQk6NvNWP6bkNIsj1QCHnCBoYsS3FxgAxrogB31teCIdEBNUqRiRkrQgg+owDK0MUgb49LN50DUPOczIdfWRyr0qnekFinABTjAABOIcmKH/0gFR7SCARNoBAxSOMITRlGZ7n6kvwgJ4AElx1wJyJi4512vQzYgAoRkAAMbcYxyMMNNT14EBBposAtjWx0Z6cYFaKajbiYgJccM0MhIHsEUKnOwAWhzIgHyDQY1qFGEgEbRZOaIGBOyZo04JgiQhotAfOCDRGdkA3McwYoRwmjdZKg6RhQkITlwAtjkJgAPgMxtNGWQBFSAC3xWs4n7UhJET1pXWBXomAGwSwCcwM4dWIKHjI3ppsjQuxK5wAU0AoIWGykAE8DXZhsaEREU4g4sokgFICBRCCzhMBqIMmIoG7xp14TTCakAbrXLkQx0AAMYWEAGgvKACGjqItBmSv+AhjAE43Wk2hrLQx0R4oEFGGDML47xUAoLAIM8yMgv7AAHqIYooBp7WFi94ATsLcIyW6Q/GM8gRQiekbfhVCML9wjNFz3QGT2CAyIwEJ8zQoIBq4Ak4jtIPwWX730vYIztmjclC6VNZFeEAhCADEQj8nKMDMQFA1G4tTuSb1jfzAIeOkDC0WQHPfg8dANugAwUB4BFQijme/3nRoQksajbLrkNO1G7OYL1jNj82nTuoR2ZNAEHwciKz1U5BUrA9hRMKXji4StGaE24lIMPPRMIEQr4rYGwbwTwFzGScC4ySISMIA1VacxZUTwaq1TgPBJILwlKMKXdPMqfQiV56gT/zt7MJxIATHhwBkb9944Y6AQn0IDabxZqohgh230QNkLka5L/KKQEKYSQZyYQgZOTa0S9hwhTXYuQvNc89BfQAtx7W0gMjGDpp9dLC6E/Q5bUGm5ESYTDpZjAi9CqQqGNCKik6ouQAqgAKPk9pJChc/EI+mmY9Eu+s+kAa3uA85gqq1g5hQABDEABE7gADfC1h+iP3HCMAYA2NXMAKamAhCsmiOg4nmu+jAiBFGgAElgBheAJxhGWLHkUkZOJppsIZImUCcS3DfATEfQ7rumnUsmoUvGJCwi9BQA1Arq4mYpCQDOe4wMAFABAi0gAHBjDHkAk6xuwD8iCCdCUeNuU/8mzLIchv4lwDIc4QnzrgAXoACb8roGwuQ5wA6uQmY8SpBEYgQfTCIGYgRkINYxQALYrgyCkk7mLM5NCqbeyQ6ZggAfzACjbCBNAAQ8gwYx4PcWivfT6gBC4I5oYwoqgJ/QLPrAwEAygwa0gxdHIkji4wRxUxVWUQ5UDgBUAuhRIxYkhxUKBgEjkRYtgxYvAAioYMMZrFxSjgAg4P2Ukmdv4M67xGmuMFl/MHraDxVu5vurgrGt0CKnaENwAAORSLpL5xooIgQ8YsCs4QFxpLIHysnPEiN1AGMeBHACLiWBsgBTIAnOkFgH8m330G+q4sFMbP6VgqoP0lbeZSAjRKf9k6caFNBkHSBb0cJ3sQw+IVIoEiByd4CqvSsbXwCfsa8ON5Jrv44zy4bFuZMaQqAs3wkTWMKMCsAB9fMmLCB4NARUBCkihIA2r8COdXApgGoggVAESUIDbsyCgzAigEg1HA5uuQBYGpLQ3IwAYgIGL0wgVGDASqMq644oBcCTfIgwB6QhbVIgBYAO24z60lDd4pAm6e8WO6A+C2AiiAAKbBABbTKgCYCpCYLvbu8s4ZIsCSDjmiLrSEAKV6IgG+AgUi7uoYI7mSq9oZMw3ykubcI4AkIAP+IDPvIjL9IjVhMvUpJ8IkCYRWkzQnBfRPCwWqEvL/IjW5AidCgq7kBL/laxNIbxNmzBFz4w7jejNjWDOUTzNPFLA61BO4lTLkXyLIEsvBNgNKXkMRXPOjABPcBywNUAPM6zOnHBA4zxO6HwtuMEYnAkB2pMAYqzB+axPSrKKk4G7yhwAIGC71ERPsBjM71iO2HCASkq0G0yvyDvJpBwAJBiwSuDPrXGUqSi7g6AQ9NNNAd0LAlWpDeQJtmsAt6HQj9yaEtWMEYU9YTNN1OxQvvjQvgC62tNQV6EIGsVBGJUPGeWLFZjHD9BBjfjRBgjSHY2PHuWLEEAA/KxBJj1SJF1PKEXL/tCmJJ3Sl9yJ8JjIK8XShUSfmdRKLx3TSAMSOFSILiVTZezH/1SLFAx5QziNUzmdUzqtUzu9UzzNUz3dUz7tUz/dESlFDDZlU6Ncxrwci49A1I4gULJIVJd0iEb1CEaVuQsJVL8A0x0TU44gUEXtiE4FzLyMVE99VLmk1Er1CFEFVcQBDHdcrkU9VFJ1iE891Y5I1Y2Y1awzVasMVV29iDRFjCqtCALl1FhVCFzFGl511FrtVV9N1ldllgSwSImIVo94gPN8CGv1CGrtS42siGzNjG6liG0FV22VVjU9V3RNV3VdV3ZtV3d9V3iNV3mdV3qtV3u9V3zNV33dV0TkOtgYgC2pj2vl1wZkxPm4ncBAiPIAEYSAisCIKYL1CrnYUrkbH/9agTvH4UEAuA3SsNiI7Qof6afZkY8O+QxN2bL+csiPdYrgvBHnaInbCBBVS1mQdB0MizlzdKeV9QhCjZD16C+UzRCV9cuBEKaHqChx2lmNSC5zfY3a6MkoGS+N5dgN6Uo0JZWaKlalDdm1tFS3cFiGxbjwCBGwhdh3jAipsiil3dQdaVrMEFh7AVjFQq1C1dm1LS39Yjqvvdun+VW+/Rm//duJCVzBDau9LVzDRdyqJFzF/RbGbdxqeVzIbRbJndxl2RPNMjvL3R3MDYCD09zNHZxdEbzQFV1bId3S7dvT9brUNV1qY93WVd3XjV3XjQjUpd3EtV3Yxd2AGd3d5d3/CAEqrvkMCJDJ0rCA8PPG2QVeHAme0aiNbUO8VBOSM1Ve3WXe5t2a5GHY4OyQD5muq11e7I2Q8FhDAppZoa1ZmSPagljd8ZUQF5nYskNf41FfhciwbnLf9z1Y/OgN6xBbRKGO//2y691f+UgPKPmeAoDep53eISFgiLhdAx6OMMEY/PAMLDFeMSlUCZ7gYPFdD/YWEA5hahlhEmYWEz5hYUlhFcYh/W3hD35hGM4VFp5hVqlhG+YUHM7hRdlhHlaKWlEJC6BK3hPfH2aKjgUVTjIPq20iGT5iSZkLCzEAu9DaZy1gKF4KxXsIJ6zECP7dLKYSHw7jcZKWlEjexsRi/zLOiQ2JgAnoSHssTiNe45vwidnZnK4YYzo+CeTlOjyOjCfGiMXa42kNkT5aELkdDcewumOpoEcL5P6ZkRohZJw4gNtwCZ7Yje8Rn478ydeC5Ip4Jrel4+G6CMA4CIBMLgqYSfThYDCuCHmKYygGW8oT1keh3/OtX/WwWVeNQVPzm4caTh6Omd2TiMahIFym2V2WOfxliRLBth6yNEomKE92FqFs5aodL4D0lR+DiFJDiAsAw2mOCS21mooAJrtAxg55ptxoR3PcE/8DgNEbZ5B4l9PBGlWrDih5O7jjRk1ViA3QCxPQAHreJu3N4xIRQULagFcuaI+gMYapvNHwAf8XcAEfEGaHlkt4k2jNCEvkyGiUsg+D9WI8KgDwA+nu2BUzooBRRumbWZ1aLuKIYEn5eZtwJWR73kuSBqlqMjkiGwAoAAS6RWl+8QqVrqZwwgj4cuiFsbG0xCWOWGp6/hhzfmqeRsd4k+pxJua8lWlqcggFtAitnuaiMWpb0aqsFueMzjKrVoi6ogCJGWtK1itKvCyofq1Nlgi5dumdduvURMaJ2Os1BphBts3Fsy29Vmt6DgAIEJXjsOJNPesAPafE5uvHqQ1aG4Cpew6MRtbDnpCT/qx9hbOW7goq3hEpbuuEkC8/Emx2TcRF7OyCG2qvvuuI8AzR5te4JA4TjNv/gKXts53pAG2Q0H4vxa7X3Xba8MiYhSXb8DDbT/7sReOb46bX5HaNL3FYjP2eqQWKqi3U12sM2qnueb1u1zCAn5iKoNXlj2TWoyYyn04I125X8/4KDCws8/HVwICM9VbZNjMXyb4ICjJuMm3KRNaI+t7K5yiL6o0IHuxv+02e67TtVpRv8q7OlAjLsUTw4VajzZmKBveVB9DsCJJaPNlY7/bYXqZwipBN6rpw9KzvBOcKBQwnK/moxlluhR3bhn1uP3rvFtnk+WZMGe9wvljg8GBWh6CQLRGI35YYIBeUBCPT6w6tIoLsrcDgt1Jt6zNykjmAIYe7gzrHKt8t0M2X/yjHGgeY7wE4pwFowRcZ2ICB7QMfRS/vNJgO8dCU7owwhBErMedRptwIly2vogwXy9KeccJQYp2266ueuSNLMhjfxlYCNM2R82K8869+s4MGZD4HI16L51ZkqEGHJFkOmCJvjaYeLUf36414MlHc0VTHDKqO6b5ebU1PCGXjuEig8lx/dJgRAJnp6lvv8o1AOn7rgdIGylm/jLJG6E9fkLxWxYOR82bfoo3mcsL89QmRbWoRLMK6aRbHCEV3CrrGdC0L8JCIGFWslZ2prY249t5V95CgunYPgNmCdw73iHJvisxl9TTe9L869XbJO3nno2yvbWDnYyXfHYPndlxnjf+BERKCv2KBDygL8PZleXh+h3i3cA50l1R63ymbhhgy4njXZA3NemCFTwgEsAEbsEuIMC2vmhZ+WjT7CBiU902P94oSmvZbf7wBo027um2TlCkCwIHK1Jedj/ee74qD8fQyAtAPm/mEmeeZZ6hHKvSKUJaQd4qm3/cZE2lib3UAKMugq/qHYPerGx6XSidYsog2Hws4nx5Egqdlt6976vl+l5Q3jLcuAQ3OwODibZDjReNJccQGgEUGGteHwHqIUCZGChLbEXRaaRKpsyqskCioUoqwt/PLkKGIrghO8ppCYWDpDRKWD26IeIFPGLLUERzIh1Q3T6cXibeuqfTquPT/ZeTlLOTHt4Ewcuf7p3d2hPBf7o0S7x3gFY+ICSDVEKL4x1+QMbcdUr9YQtGmqrqqDZqorBuArSvWzw/A9nyzBD7PBUY8CF/mQk0ezyp6i8j46b8MvEc+2A9AiM/OBpB5uACIAQIiEJgwoQCAhAoXMoQgIAGAAAICRJwokACAiwsPDOg4AAJFhiIBIBxpEgACBSdNQlyIYSXMmDJn0qz5subClDgXSpCwE4CEBkIb+Pxp9KjCAA4SFhAwQGYBBw8TJhAAAYDDBAYGAqh6VeEDAmIJRAgZc4CDkjF10ixQ1iXSuHKR3vzJ9mdPnBQMIBjaAMHcwDIrRDCQUcABmREG/4pNUMBgAIMICQh4IPWpyQBmY0L4ulZlzQMP4AoubVpk3Z13d+al6SDCUwkfPhQ9bTuhgQkCdi+VObYxgAMQCEBITDKsBQorNddUC3N1W+UAUt+uTvco9JqtVyZwMNqwwgsXrFcXTuCBc/ILmdfs/PknhQlGOGAYAUI9fpvYQeOtzbBAAhRRIB1D4uUnmAMVpHdgUptB5UBLJ2U3EyMYoGACChpkwCCHI1FX04QzbafQUxU4QOBIBnaI1G5Wocghe82RtFKIMV1wgkIjoLAij9PtZ1QILbQQgkIHTBDBTCr2uBOAUg0UwILqxYhTBBGKVCNMNyrUwY40edTRkkd9SP8TlieF8IFQHwgSQWLGyaRkmDsZ8MBumDE4ZU0DTCAhfzgxoAEDADCAQRvg+UYADmL9pBmjHHbkApiq9UlTEn458mJMDCywQKBx6uVQnR3iyeRIZa7kgQYYaECKQ1GeNOZMmgUx6lkeuUmTWEIoKulPlQ6VBE6onnCCBiJ4OtMDuu0GgZ13OqjXBIYqZCpOATArE6w0ZQuTWImO9lMDP9JkAAQOnJkmkTMVcACgCXmwwbEy8eZYj7S259m0k8pVAHPSehjXtjEFDFO4RlEbXEYQGBbCFlukC5NhVRGQ2sDxPnArj/biVIBzB/80AQH+kibmdUcVbJe+IxWEcQcdxHT/QAR7cgzABh4khAIH8eq83LM/QWBBTikHBmABBlipUMUrJW3S0iOdzKtJACpHgXMgbMDBBhuYIFIBlBmwLkMiaDDCCBrctzPaDGncnAN2enzUABH0NrJRTaOG1NM1mQAJGJ2KNFyzCi0wHgAdjKAQBBM8RfVJGHqwYdqRJ7Q2qSgJfVpiAUCUAQoY2Ewy6EblPdOgJ1ygAeEAkLun0gplgEGCXWEsOe0wUU4lRG/LNQABqGwwwgUcLBD6T3a7jkIOn9e0QJcgYNBRBcPNSQBEYVVPvQZbC7oB47V7H2vPR8FseYcoHA5ABhv4jZPxCjkPeU0ZcAA8BzmbdEAFTz0Q/8FonCJNSVkC8BSOGIaAwRmAAS6wARGgqkvfe6DtwheXKFyuOkoaQSYwUgAEyoRzFoIfTTqggQV4DifmS0j6RDAAzVUEaNGDiAGMA7yE/Gl2MPHAppQHwR2O5HY7CYMSGpCCh+EHBcNDnwaYoJwDFCQjBKBI0Rgiv8EtwH40wdmGnKc9hhhgAIlZIUQSQITUdeACFGDh11aihiMsoAMYmAMP41gaH9bkXELxj3rktwFiuUwkBqBABbpypK5oDoeC0yFuvKg6RR4gAH5Q3gI4cZ6KYCQBkwSj6jZhvwyYTV0BKMUb9kCHM+BRjqZclAQN5pcK3kYEFzjbTBpZASVdIP8IGJFIJSdpydEESBM4SsgGjKDImWCNj1ApmgUGsAISCJGIp3xmTehIEzs2AAip3Nm7NpTCmoAAdQwYgRVrIoIcwHIlFZhAIKGpzrhIkybLFCIWlOMqtHVgA/XsIzdHsIATgLAmo/vP1AK3TggOkyQBoldCzlgBka3nmnPJjUMV8huMcMiV62PQP0kEsoGaspECoCgApEKZ3tDJAQZh6OQiKhfhzJMhHZFBpDgak4xqZYMylSNlPppQAQDNAgKgmgD2VIHKnKSdcrFAOmd605n80wEEsOFSv6eRilBEIgLU6VR7qNLAxA1TTouqUhUSINWB1ZRTtSpVNZJVAIRlLG//6dAAvLqQjJY1IScjjFzr6r2pDnU0dKrAAQSwFArwdCNfAsmK9JRKuoI1BEFRRBOgqtfv4U+wAyjaQOImAMMshgI+PVpDeRRFqDI2qikYChIme8qchioBi6lSQg4glQl8KzNbtY2RajvXFTHKqBmxlV78UlrVEte3pjFAz4ZrG81Y87YJydUkZ7I4ZgqFBMS9blGdW50JbEa5IpmoyfA2rghEACErQNMHVoDd9apNu7eRraG869IBwFSgNJHvV8+SGCuFAAHOZC92jWudCkAEvwwxsEgQvFuYQAA2AH5wdnc2gCZcgSj/lYmCFyy6kwzgOxD+sFbRdlqhIAGlK8mw/0JQDICMGsm9IK6rgK0j3OAQIKlhDS+OSUS9F/NYJDGuDnUbYF0AjcazoD1wXFScNwtAqcdOTinaztuA9HKxAhRJwLUSnGSjlOC0KmDi3J785B9Xp78XVghyq/qAhQVFAmdey19+EuQZNFnMYiazpzoMEVMMJQV4GUop54sQzURhlXY+NJ51JtynAkAsmQuAYTRjmI4gBE1pgjRWGB0qR0ckAHzwi58PfWcXRy7IJLjsbweNaUk3mtGWnvKaAZC/liYkKEIugahHLVMpU5k1gP5JCQCTa13L1MzYkYCwh61s8C272c72MamfLe31Jnra1i5rta+tbZlme9vejhxHaP/d6W+T+6ZRadGRQ1vudauzr01hXYTZLW9TUuYp9ebZvPPNw3vfeyEBYpRYeivwgRO84AY/OMITrvCFM7zhDn84xCMu8d6a+Kb8dgpD/q2ZgEc8AiCJOMch3mCJe1ziIX/4yEH+xI5//OEnf7iDVevuoEbwKASwL7ONwjub41wmMd65UWJ886BHe+iqPfdu0t0gnh/l5yDdidFRCbenV4vUUa86Uq4+2XDHROg97zqpgf4TrUcz7FQvO9OlnnZij/3rNdf52XHldnzDvemkvhjRkYJ3O8d47z8xQMVhIhrxiZvDcz8J2IwC+BUtPt8JULq+Iy/5yVO+8pa/POYzr/n/za/TAFbO6/2apdDAA4jVsdWMZJlyxgC4qZGsh0pMPR8A0JPkS8aRPe1xY+WWlB6hUfsSqntP69IriCkHHX6AUDR6xHNQ97NXiPABnJsJSEW3KzGabsAi2JMup0XRAgBhyfvT7rdocQPpLGd2gxuDVH8lAmkRRqbffu4ElQBAC+lHBev+FoVKpPpHvP8dBP6N1Eqc2/yVFPeJxAD4VEjIH1EN4P+t118BgG4UnkSoH0nQXF+5n2EwIP4dQGCFmQIahkNQhFSAYASaBGFh4ARWIIdZliK1oADM01aUl0IQVk+N3+8NQFVsFg4CgE/llUAsRb39YBCexAYuxtdo4AMy/0SLhIQMFoAR6iB2XdzhJQQGqpVOpR9EYCAGLsdrGIYXCkABchcGWuELgozCNBrG9dtIDJVJCUAgoRVaMZhVUBUeRo1UvMZV0OFEFBVR1ZsWxl0eWqEfRhu9tSHGzUQWYtUWrkQIYiEZAsAXngRZsAklTmIlioQFLMUZKmLPCUcAECAaZoaL6AZy/WEdnsRWbBYeriLXJM5ipMUhsuJuFIRTDKIphoQhquIfrtcRniBNYGAk/iB3UF9JVOC7yYRGKCPNnQT/qV8wIoa8kOE0StZQUUS9beAEroRDfAU3yiES/iEDhqONiUQjuRYZFmNh9dAvXqM5sldVJAdXyEQX1f8JZ/3UZ5lTUD0AC5WgROALJ4KEVFwFQN6h4b3fU8xj+C0Hk1FGJfFUQ9piBMTHQdSgZlXc+4EHRirhSVRF20iFVmSWR37kAj5gZ+2jAn7jQkokV3SkK7JXsghW6q0H/1GEbPUjt/CfBvkUT7VUZCwLQhSAT1pA4X3hTDpA6lHAYvxkQiRlTaojJnbFa0EeG+qWVFrlTL5VVsLEbrxVcMyW9SlEND6lbiglVVQl560lW7alW74lXMalXM4lXdalXd4lXualXu4lX46EVjhbTOFEYPbldwmg2GXdFX5YdwSAZdRkiBGmSRAHRewc8ZXEQTFFBRRfRiCXdBAAIBWf7LX/BODFEKoFx9dwhACZJm44JgTlRknETUI8BaoFCHgcgOelk2bQpkEFQPGtywbZ5mpuJhoZh01h3s2lxc7hzwBUAEY8ALM8wGVViWshhEWcSKMlB2JRQAJ8RFU5gHdAQEsURtzMXnnBDOBN5TpFz0Jg4kc91RNRQNtc50eMhlIkAHMGR/7cZ9w4FZYlBHhSInS2TVQoB4Rk3s0FCNAZjUQAYZ0lwLc8QBcmFNAMHdDhz3BExFegBfhhBNANXXfsGEdNydC5ogH0BgVcxdA9xrhRIm4ECBmixVAexGNQJ5TBjHsY6FOcSCVBiECoToMVBnswxyTuHIVixM8A0i2ZRdsk/4cTPRdm2N9NVYBusWdsUhSRYgYZsgcZdsd2vihI+aOUYiGURQS8GedCKorRkWFJ+KNn+adyTGKYFimLNmmMWBKSNGmjnSmIDpRrxuadTqKKdsVoDJ1srSgZpimeqg55gcckMgfMOKfmGR1BdIUDBIBPASFIYCJxXCglQoBlGIac/kxbrWhCTEBLdKgXlZcBoOc6LWZjiunknIcDgOoTWaeWUqqleulCWIBnNCqUxGeBYt4BlEQMxZZsGqtagCBZdlGRDKVxeBHYNB5J2CBJGMewAqfqsCYPBWazMOtzUUBpNh5mcERGVOtCRB1mjCZxJmZcTmLeLRvZeQkhQqZJsP8rOhbeiw3rUUgrvfarv/4rwAaswA4swRaswR4swiaswi4sXa5Q4EkOCznsTozVQ6Umw87FUFFjVzCaxcyrE+aStp6ru/6EJX3RL8ZJydalk3xLFyGEIiEQqpFrRiTG6tFLpAwm7uEG6tXeH6VmiTqFYRTA5xlrcDRF/KGaF6UjifCmv1AGZj7fAd3ma84etDoEYAnE7FnsSCSt1q7QQvFs4i2f0EItAWUmx1htyFpeYDkE60jEUwyEbhCWCW6WQIzGR4kUEG7WVtzfThGEU4BkZwmEsjjFBU6EkchNIAqWU+iU21Li4FKEQxTE90nUOh5J+1GGskSk394c/Alu+Zn/RFC9xvhF7kkNoU6JFEEc7uUG1S2+3yPCJZ0cwBE2bmY9BcjUoJVR4wGc0WJ0hRwOFYrEDELYJnnFFU8JxFVkIxv650/FzZ5QBrgabUW8bVoEVsgcr0TYmNM6BLjGDBt+Te9KBiXeEsYhr6yd7MeqDk/t7QrJoUAk0wFURUicaPN6r9e4RZYuolzqxigWFu2ClE8Rxs+QRXAcyf5MouXeKVk+Xf2JBXT+IdYuLxv+hgSP7/Ra8PgKBEEAB+VO8FhIsNNuIeOWLwSj70KIMOduMPVE8AU/V3ui6SQ6bePKJUiKBSr+r1j14wr24U+dG/M2YUKYVGIAlkk9xR9FcART/wbHTCCAVPAIvy1FfVRTzOoBiSxbiWMTO+3yCu9WkC/VILEqEoBz6FRVoIdgFVBH/CJhXQVyMTFEaLEM97Bc+hR4WC0OM0WdNMX4GcluZF9w7Ia/wEyLgGBTHm8JV9VuQAlrPa+7PjEGk/Hgaq+aLjIIb2kfO+JHgTFFRADfSiJvIEQCRDILX/FuGCUlw/GL3qJcxp4XtezMGhbRJhJpxtbrGpahcERibFDQNh/XLdK42okiufIwFVRHBLKddNEvEy1prrEs6zLPbkXgfJTMkggHOTP0sXIyV/EiPSzBZoVeFS6rssTZ1fLF5sc011VHpK0CqnM5t7M7vzM8x7M8z/8zPdezPd8zPuezPu8zP/ezP/8zQAe0QA80QRe0QR80Qie0QjMspZWG0czEX+6OvS70aTClP8JWTDzeWXjsuU40qX70y4ylJVI0xFArwgitZiIQC2EFs/gmcK4QZhwm+JkeSscnIcU0ckUITOMGeAQIYi3E2BYQR8Zv2xgGcvUmahqxU7DzQKsnUEunDVYGWtjbExkAAfCnpS7gZFIddDIlx0AIUz4FSPDOmwboU2Q1k40bk/HOZnRNAsBnDBXGqjZSWXiRZ3ZHRpSFV2OtVSo0njjoU0bouLEHiNqgWySq6gUAbPRnnq4q9GCErwKAYSOJpN3plCRAMnEnpe4Y0I3/9VSj6pyStEk49dKNW2QTNpaSJWLDTP60DWqPZ27OqZCqtmYA3ZSMIqM86f11aMt1EUWNqGizogDGVptixZtCGWoHcWKUKGKjNmPfXJ/OSGSjJXNX9phSBUiBMnB0tlls0G+/bXB/JP8o9ht3RhRD2XgyEWbAp1Iox2HCjKXCRlQ8wP4sZFm4R2Szt61CrgWEhYMMh6UClqqyyWPMXlQQJEd8d6NBwDmGNzVvhJukK0cOkFpsUEkkHppdlr5mhG8yxTDztIcTa22Oph9xELYWq4Ujq7kWbWxys4O/OIzHuIzPOI2bxBGV240jdPuI2o7fMwYwAJAHuZAPOZEXuZEf/zmSJ7mSLzmTN3mQ73hDC8ZDl0ZEyxsGbAqWZ7mWbzmXd7mXfzmYh7mYjzmZZ7nxWDR5y4RGw4RMc3SExetJ+B1MrDl79bid2c2qJitJmG2Lr3RnaPi6TJrFHiY0L/dKC6dostriaR0mFedmJghmIGhsSS1LlyZ22bmY2Q1pMwVUU6dZtxqkXTX1oPVWLwRfo8UZRbFZr6p20qc2Ngtmd9hoeCpbKUzJYYUAeeZ1nqg2VjV7pQ65AbvPOQhgs5VgMwdhh+dQIolMTyIESAcV+yrMuAlzXF1FpjFJeEda5KmiPja371y3HfSmr+hsDzYvpraYNruTrntkW5IqvvoJ9/9WbGoshQYQC8lpuBt0dAdHcT+7bFfVuSu36iyFurNVOkV1Sl14lsK7QsTcUFbqtg9ddE+GbCZpjWf0eMPWpp73uKW30em3e1MdcSyUdzwRrKJeWfDquF3do1oGrtd6ROjSfaNoxef16128+zWLssYmiC8Si4c4U8xO8zVfuarOLt9eAS0ImDh6zK6rtTprIuG81MuFByBSP+e4vsGJP2P6sl1ABzg52Ie92I892Ze92Z892XO9silQmbe927893Me93M893ce92g+b1vfz3eda3vPz3osakAu0sE894Re+4R8+4ie+Xg6mAeU8vkZEYFS54lN5pb7qgSuFZ3hckfD/z/70NaxCXbPA+f2IdGQafnTDZpjGVpUON5OqPvQFiGbmNKBaGXiodIToJovXdOActcuWhG12BwfxvtHrZqET/qazSXdgDHj+J0szlHLep2xp5yS/dbR/+nvG581FxVvHXGzd9VLgNXzyS10zkXYuRX3q50R4fniL6FmLlHEcRHEXQINNgFFykYtiRUtsaWYjlq8ChAEHAABQgACAwIAEBxEOIEgQQoABAxw4hAAhwgEAAwhAlEhxQIAABAWQfHgSZUqVK1m2dPkSZkyZM2nWtHkTJ8EKD05mPJlgQsEIIgUUOFnggYWfDhIMKJnQZAACIiUCKAlAJEeCWhOKJAj1/yGBiCINkKywtSPCsQEMeLVqMmdcuXPp1rV7d66BCUY3RgCgkWCBoBEnWkjw9yEFpWEdvoVw+G2CtACMXhUpmGACngkXfm3s8aFRCA98agUQMbTbq1fxtnb9GnZs2AkcBHjgQGOCCA8CMAWwl6Di07VvA85c20LJA0MfXIUw1cJZyyOl3i6bsICDB6Q/U3YQEbfkgg4KCA5AITv4A6q/QjgrG358+fPnTzw60WgB4xsJGrCf8gCHGitAwIf8K4s/AAxA0L+HDuBrAP34OilAoyIk6ICyCOSrQgUR/GwABOkbkcQSTSxBBRNVnE+FElZ8EcYYU0JAARlttEsBBFz6z//BEHe88K6RbhySLhqJPPKmHFmizTbcvAOPIQAiiHK57SKADEOebIKKtZge2K+lBLBEUj4EPlAAzTTVXJPNNt18E8445ZyTzjrj/EBHlfSC0K+dHEQLOAAsoODPh2jzsS3I9AupsZAqMOrBt1BKoCoDANvQgQocKqACtrZKFCIIgCQTPgRsQADVVFVdldVWXX0V1lhlnZXWWmM9daUKopTyANrAfOyxUEU8KYChJnKAAqn6Oi+CAiioqIKzuESJMALQQxYApgyYMoACCEjg2bIEeAAkhKYallTYjEyXXZaUVMktz7ByQAACANtLOMowmsCCCTdKCwJCs/UvrYQqsED/xGkNjGCiCjpa7iJ5E7BgItSmw0rIdmN74QuNPT7pixdy1ZIgnwwNioKhAijqqKROMg2shGCOsLcJCFV4K5UDgCyAoOSViiqHLo7346KNpm/PnBELbLCPDFu6oMXQIuiB95qdmS8KOsJZwUAh3Y0hqMQLTFKviD4a7bRdY7I4AHTjzbdAhYOAOCdDm+A8gR6Y6l/PHO7tMK7dHuqi7BzyrbrToJOOIK8GGApMtSWfPCceKcOPsv0a86+70ID0MXMMjTpQ9ATv08jSwBo7ADDSE1ywv84pn5322m2/Hffcdd+9pnV5//0uVIE30ffhjc9JAgmOH9FUW51/HvropZ+eYPrqo09B+eXnM9PO7r3/HvzwxR+ffPBJyF77+IpPn32Xkm+/1Brhn3+l9+l/LQSR79+fIBVS5B+AARTgAAlYQAMeEIEJVOACGdhABz4QghGU4AQpWEELXhCDGdTgBtsVEAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental analysis-percent airway centerline length versus (A) mean airway cross-sectional area, (B) minimal cross-sectional area, and (C) volume. Data points represent mean values &plusmn;SD along 10 percent segments. Dotted lines represent estimated measurements between data points. Solid blue circles = subjects with obstructive sleep apnea; open red circles = control subjects. Regions of the adenoid and tonsils adjacent to the airway are shown by horizontal bars. Note the overlap regions for tonsils and adenoid.",
"    <div class=\"footnotes\">",
"     OSA: obstructive sleep apnea",
"     <br>",
"      * p &lt;0.05",
"      <br>",
"       ** p &lt;0.005",
"       <br>",
"        *** p &lt;0.0005",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Arens R, McDonough JM, Corbin AM, et al. Upper airway size analysis of children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2003; 167:65. Official Journal of the American Thoracic Society. Copyright &copy; 2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22288=[""].join("\n");
var outline_f21_49_22288=null;
var title_f21_49_22289="Mirizzi syndrome with compression of the common duct";
var content_f21_49_22289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Mirizzi syndrome with compression of the common hepatic duct by an impacted stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of Mirizzi syndrome.",
"    <br>",
"     (Panel A) An impacted stone in the cystic duct or Hartmann's pouch of the gallbladder obstructs the common hepatic duct both by extrinsic compression and associated inflammation.",
"     <br>",
"      (Panel B) Treatment consists of cholecystectomy.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22289=[""].join("\n");
var outline_f21_49_22289=null;
var title_f21_49_22290="Ultrasound guided amniocentesis";
var content_f21_49_22290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Ultrasound guided amniocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial image of the uterus demonstrating amniotic fluid. A needle is shown traversing the maternal subcutaneous tissue, uterus, and fetal membranes with the tip of the needle centrally located within the amniotic fluid. The fetus is not visualized in this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22290=[""].join("\n");
var outline_f21_49_22290=null;
var title_f21_49_22291="Single vessel grafting";
var content_f21_49_22291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graphic representation of single vessel grafting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left internal mammary artery (LIMA) is anastomosed to the left anterior descending (LAD) artery. The coronary stabilizer prevents movement of the artery during the surgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Stanbridge RD, Hadjinikolaou LK, cohen AS, et al. Ann Thorac Surg 1997; 65 (6 Suppl):S53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22291=[""].join("\n");
var outline_f21_49_22291=null;
var title_f21_49_22292="Valrubicin: Drug information";
var content_f21_49_22292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valrubicin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33315?source=see_link\">",
"    see \"Valrubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Valtaxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Anthracycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bladder cancer:",
"     </b>",
"     Intravesical: 800 mg once weekly (retain for 2 hours) for 6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7801925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     In clinical trials (Steinberg, 2000), treatment was delayed for 1 week for the following adverse events: Grade 3 dysuria (not controlled with phenazopyridine), frequency/urgency lasting &gt;24 hours, grade 2 gross hematuria (without clots) lasting &gt;48 hours, grade 3 hematuria (with clots) lasting &gt;48 hours. For local toxicities &lt;grade 4 (eg, dysuria [not controlled with phenazopyridine] or severe bladder spasm), anticholinergic therapy (systemic or topical) or topical anesthesia was administered prior to subsequent instillations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valstar&reg;: 40 mg/mL (5 mL) [contains dehydrated ethanol 50%, polyoxyl castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravesicular bladder instillation: Insert urinary catheter, empty bladder prior to instillation, slowly by gravity flow, instill 800 mg/75 mL (in 0.9% sodium chloride injection), remove catheter. Retain in the bladder for 2 hours, then void. Administer through non-PVC tubing due to the polyoxyl castor oil (Cremophor&reg; EL) diluent. Maintain adequate hydration following treatment. Use appropriate protective gown, goggles, and gloves during administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravesical treatment of BCG-refractory bladder carcinoma",
"     <i>",
"      in situ",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valrubicin may be confused with DAUNOrubicin, DOXOrubicin, epirubicin, IDArubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valstar&reg; may be confused with valsartan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The medication is in a class the Institute for Safe Medication Practices (ISMP) includes  among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, local adverse reactions occur during or shortly after instillation and resolve within 1-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Genitourinary: Bladder irritation (88%), urinary frequency (61%), urinary urgency (57%), dysuria (56%), bladder spasm (31%), hematuria (29%; gross: 1%), bladder pain (28%), urinary incontinence (22%), cystitis (15%), urinary tract infection (15%), urine red-tinged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), vasodilation (2%), peripheral edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%), malaise (4%), dizziness (3%), fever (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (5%), nausea (5%), diarrhea (3%), vomiting (2%), flatulence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Nocturia (7%), burning symptoms (5%), urinary retention (4%), urethral pain (3%), pelvic pain (1%), hematuria (microscopic) (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4%), back pain (3%), myalgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hematologic toxicity (following instillation into  perforated bladder), nonprotein nitrogen increased, pruritus, skin irritation (local), taste loss, tenesmus, urine flow decreased, urethritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to anthracyclines, polyoxyl castor oil (Cremophor&reg; EL), or any component of the formulation; concurrent urinary tract infection; small bladder capacity (unable to tolerate a 75 mL instillation)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyoxyl castor oil hypersensitivity: Contains polyoxyl castor oil (Cremophor&reg; EL) which is associated with hypersensitivity reactions; use is contraindicated in patients with hypersensitivity to polyoxyl castor oil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Red-tinged urine: May occur in first 24 hours after instillation. Prolonged discoloration should prompt contact with the physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder perforation:  Evaluate bladder status prior to instillation. Do not administer if mucosal integrity of bladder has been compromised or bladder perforation is present; delay treatment until restoration of bladder integrity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder procedures: Delay valrubicin therapy for at least 2 weeks after transurethral resection and/or fulguration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritable bladder symptoms: Use with caution in patients with severe irritable bladder symptoms; irritable bladder symptoms may occur during instillation and retention, and for a brief time after voiding. Prolonged symptoms should prompt contact with the physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Use aseptic technique to prevent urinary tract infection or traumatizing urinary mucosa. Although clamping of the urinary catheter after administration is not recommended, use caution and appropriate medical supervision if performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Delaying cystectomy during treatment may lead to metastatic bladder cancer; reconsider cystectomy if complete response to treatment does not occur within 3 months.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and teratogenic effects were observed in animal reproduction studies. Systemic exposure (eg, with bladder perforation) during human pregnancy may result in fetal harm. Women of childbearing potential should avoid becoming pregnant during treatment. All patients of reproductive age should use an effective method of contraception during the treatment period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F233106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued prior to initiation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Valstar Intravesical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (5 mL): $1202.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cystoscopy, biopsy, and urine cytology every 3 months for recurrence or progression",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Valstar (CA, IL);",
"     </li>",
"     <li>",
"      Valtaxin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks function of DNA topoisomerase II; inhibits DNA synthesis, causes extensive chromosomal damage, and arrests cell development (G",
"     <sub>",
"      2",
"     </sub>",
"     phase); unlike other anthracyclines, does not appear to intercalate DNA; readily penetrates cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Intravesical: Penetrates into bladder wall; negligible systemic absorption (dependent on bladder wall condition; trauma to mucosa may increase absorption, bladder wall perforation may significantly increase absorption and systemic myelotoxicity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Negligible after intravesical instillation and 2-hour retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (post 2-hour retention): 98.6% as intact drug; 0.4% as",
"     <i>",
"      N",
"     </i>",
"     -trifluoroacetyladriamycin)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newling DW, Hetherington J, Sundaram SK, et al, &ldquo;The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer -- A Marker Lesion Study,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2001, 39(6):643-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22292/abstract-text/11464052/pubmed\" id=\"11464052\" target=\"_blank\">",
"        11464052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinberg G, Bahnson R, Brosman S, et al, &ldquo;Efficacy and Safety of Valrubicin for the Treatment of Bacillus Calmette-Guerin Refractory Carcinoma",
"      <i>",
"       in situ",
"      </i>",
"      of the Bladder: The Valrubicin Study Group,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2000, 163(3):761-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22292/abstract-text/10687972/pubmed\" id=\"10687972\" target=\"_blank\">",
"        10687972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10309 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22292=[""].join("\n");
var outline_f21_49_22292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233134\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233119\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233120\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7801925\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233097\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233082\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233100\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233098\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233140\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233132\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233103\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233086\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300204\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233093\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233105\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233126\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233106\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324072\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233095\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233107\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233085\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233102\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33315?source=related_link\">",
"      Valrubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22293="Peptide hormone signal transduction and regulation";
var content_f21_49_22293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peptide hormone signal transduction and regulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22293/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/49/22293/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in molecular biology over the past 20 years have expanded our understanding of the processes of peptide hormone receptor binding and signal transduction that were previously impossible to study. The DNA sequences for hundreds of receptors and many signaling molecules involved in their regulation have been analyzed.",
"   </p>",
"   <p>",
"    Signal transduction is a process in which a peptide hormone transfers specific information from the outside of the target cell to exert a cellular response. For this to occur, the hormone (eg, gastrin) exerts a signal through a specific receptor that transmits information from the extracellular compartment (blood) into the cell (acid-secreting cells of the stomach). This message is tightly controlled, especially in settings that are vital for cellular homeostasis.",
"   </p>",
"   <p>",
"    The normal function of a cell depends upon an intact signal",
"    <span class=\"nowrap\">",
"     regulation/termination",
"    </span>",
"    system. If this system malfunctions, the host may experience pathophysiological consequences such as abnormal secretion, motility, growth, or even the development of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major physiological principles of cell signaling systems will be reviewed here. Discussions of individual peptide hormones are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECEPTOR STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the vast array of information communicated to a cell, the basic components of the signaling system are relatively simple (",
"    <a class=\"graphic graphic_figure graphicRef74916 \" href=\"UTD.htm?0/11/190\">",
"     figure 1",
"    </a>",
"    ). A peptide hormone binds to a cell surface receptor and stimulates activation of an effector system. Cell surface receptors are capable of interacting with only certain chemical messages. The specificity of the hormone-receptor interaction is responsible for the unique cellular response.",
"   </p>",
"   <p>",
"    The peptide hormone must initiate a change in the receptor such that the hormone-receptor complex activates an intracellular effector molecule such as a specific guanyl-nucleotide-binding protein (G-protein) (",
"    <a class=\"graphic graphic_figure graphicRef79723 \" href=\"UTD.htm?18/55/19326\">",
"     figure 2",
"    </a>",
"    ). Most peptide hormone receptors act through G-proteins; as a result, these receptors are called G protein-coupled receptors (GPCRs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     G proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;G-proteins are molecular intermediaries that initiate the intracellular communication process (",
"    <a class=\"graphic graphic_figure graphicRef79723 \" href=\"UTD.htm?18/55/19326\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. After the hormone binds to its receptor, a G-protein is stimulated. Stimulation begins the intracellular process of signal transduction.",
"   </p>",
"   <p>",
"    G-proteins are composed of three subunits (alpha, beta, and gamma) and are classified according to their alpha subunit. G-proteins that stimulate adenylyl cyclase are classified as the Gs type; those that inhibit adenylyl cyclase are called Gi. To date, 20 different G-protein alpha subunits have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shortly after receptor stimulation, a series of events are initiated, which ultimately act to turn off signaling. The principal events in this process involve receptor desensitization and internalization, which reestablish cell responsiveness. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Desensitization'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Internalization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     G protein-coupled receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;G protein-coupled receptors are heptahelical proteins, with seven membrane spanning domains [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/5\">",
"     5",
"    </a>",
"    ]. They contain an extracellular amino terminus and an intracellular carboxy terminus (",
"    <a class=\"graphic graphic_figure graphicRef63760 \" href=\"UTD.htm?0/20/324\">",
"     figure 3",
"    </a>",
"    ). When stimulated by the appropriate chemical messenger, the GPCR undergoes a conformational change that causes coupling to a specific G protein. With improved understanding of receptor structure using x-ray crystallography and computer modeling, G protein-coupled receptors are becoming more attractive as drug targets [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GPCRs are classified by their structure into three groups (",
"    <a class=\"graphic graphic_table graphicRef52173 \" href=\"UTD.htm?2/51/2875\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group I, the largest group, contains the receptors for catecholamines, many peptide hormones, neuropeptides, and glycoproteins.",
"     </li>",
"     <li>",
"      Group II contains the",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"        secretin",
"       </a>",
"       /glucagon/vasoactive",
"      </span>",
"      intestinal peptide receptor family.",
"     </li>",
"     <li>",
"      Group III contains the metabotropic receptors (eg, calcium-sensing and glutamate receptors).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effector systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following receptor occupation, G-protein subunits cause activation of enzymes or other proteins, ultimately resulting in a variety of cellular responses (",
"    <a class=\"graphic graphic_figure graphicRef58612 \" href=\"UTD.htm?38/62/39918\">",
"     figure 4",
"    </a>",
"    ). Enzymes, such as adenylyl cyclase or phospholipase C, generate specific second messengers; examples include cyclic adenosine monophosphate (cAMP) and inositol 1,4,5 triphosphate (IP3) and diacylglycerol. Some G-proteins couple directly with specific ion channels, such as potassium or calcium channels, and initiate changes in ion permeability (",
"    <a class=\"graphic graphic_figure graphicRef58612 \" href=\"UTD.htm?38/62/39918\">",
"     figure 4",
"    </a>",
"    ). The effector systems are not understood for some receptors such as receptors involved with cell growth and differentiation (",
"    <a class=\"graphic graphic_table graphicRef82351 \" href=\"UTD.htm?5/42/5803\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adenylate cyclase",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most studied effector systems of receptor activation is the production of cAMP. As discussed above, Gs coupled G-protein-coupled receptors stimulate adenylate cyclase to produce cAMP. A conformational change occurs as the hormone binds to its receptor allowing the receptor to associate with Gs. Under basal (unstimulated) conditions Gs is bound to GDP. However, GDP is released during hormone binding and is replaced with GTP. The Gs-GTP complex then activates adenylyl cyclase, resulting in the formation of cAMP from ATP within the cytoplasm of the cell. cAMP is then capable of producing other effects within the cell, ultimately leading to responses such as secretion, motility, or growth.",
"   </p>",
"   <p>",
"    The G alpha-GTP complex is gradually inactivated by GTPase, which converts GTP to GDP. This enzymatic conversion occurs spontaneously by the G-protein, which is itself a GTPase. The conversion of GTP to GDP no longer permits G-protein stimulation of adenylate cyclase and is one way by which the hormone signal is terminated and the basal condition is restored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Phospholipase C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other G-proteins, such as Go, activate the phosphoinositide system when bound to hormone. Phospholipase C (PLC) acts on inositol phospholipids found in the cell membrane. As an example, PLC can cause the hydrolysis of phosphatidylinositol 4, 5 bisphosphate (PIP2) to 1, 2 diacylglycerol and inositol 1,4,5 triphosphate (IP3). Diacylglycerol and IP3 can then act as regulators of cell metabolism. This pathway can alter cell function by increasing intracellular calcium levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SIGNAL REGULATION AND TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even while signal transduction is occurring, processes begin that will terminate receptor responsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the cell to respond to future stimuli, signaling must be terminated completely and in a timely fashion; a process known as desensitization. Desensitization begins within seconds to minutes of hormone binding, and eventually results in signal termination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desensitization is the primary regulatory step that assures appropriate cell function. It involves the termination of receptor activation by receptor phosphorylation, which is initiated by specific G protein-coupled receptor kinases (GRKs) or second messenger-dependent kinases (eg, protein kinase A and protein kinase C).",
"   </p>",
"   <p>",
"    Phosphorylation of receptors requires the recruitment of proteins to the hormone-receptor complex, which participate in regulating signaling. One of these is beta-arrestin, which is located in the cytoplasm of unstimulated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/7\">",
"     7",
"    </a>",
"    ]. Upon hormone receptor stimulation, beta-arrestin is translocated from the cytoplasm to the cell membrane and assists in signal termination and subsequent hormone-receptor internalization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Internalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the receptor is adequately phosphorylated, the hormone-receptor complex is moved from the cell membrane to the inside of the cell, a process known as \"internalization.\" Internalization, which may also involve beta-arrestins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/9\">",
"     9",
"    </a>",
"    ], permits receptor processing to occur, which will most likely result in receptor dephosphorylation,",
"    <span class=\"nowrap\">",
"     removal/degradation",
"    </span>",
"    of the peptide hormone, and receptor degradation or recycling. Regardless of the eventual fate of the hormone-receptor complex, the goal is to reestablish cell responsiveness, so the next hormone stimulus is capable of sending the necessary information into the cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Beta-arrestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrestins are cytosolic proteins that are recruited to hormone bound receptors and bind to cytoplasmic regions of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/10\">",
"     10",
"    </a>",
"    ]. Once bound with beta-arrestin, the hormone-receptor complex is \"targeted\" to a specific endocytic pathway that turns off the signaling process. Endocytosis is the process by which the hormone-occupied receptor is brought from the plasma membrane into the cell. The eventual fate of the receptor depends in part upon the receptor type. Some receptors are rapidly internalized and recycled back to the cell membrane while others are destroyed and only newly produced receptors are expressed on the cell surface. While beta-arrestins were first identified by their ability to desensitize GPCRs, it has been recognized that they can stimulate signaling pathways independent of G protein activation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Non-G protein-coupled receptors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Receptor tyrosine kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some peptides signal through receptors that are not linked to G proteins. One particular class of receptors possesses intrinsic protein tyrosine kinase activity. These receptors are comprised of an extracellular domain that is usually glycosylated, a single transmembrane domain, and a cytoplasmic domain that contains a protein tyrosine kinase region and a region that is a substrate for peptide ligand-activated phosphorylation.",
"   </p>",
"   <p>",
"    With peptide binding, these receptors either phosphorylate themselves or are phosphorylated by other protein kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/12\">",
"     12",
"    </a>",
"    ]. After activation, these receptors initiate other intracellular signal transduction pathways including Ras that activates MAP kinase. MAP kinase, in turn, modulates other cellular proteins, particularly transcription factors. Specific phosphorylated tyrosine residues are also binding sites for Src homology regions 2 and 3 (SH2 and SH3 domains) that can activate various signaling pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of the receptor tyrosine kinase family include receptors for epidermal growth factor, insulin, insulin-like growth factor, fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor, nerve growth factor, and macrophage colony stimulating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Receptor serine/threonine kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receptor",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinases such as TGF-beta receptors contain a single transmembrane domain. Stimulation of these receptors activates endogenous",
"    <span class=\"nowrap\">",
"     serine/",
"    </span>",
"    threonine kinase activity which modulates cellular protein function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC NUTRIENT SENSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of G protein-coupled receptors originally identified in other tissues have been found in the gastrointestinal tract and may sense nutrients in the intestinal lumen. Many of these receptors respond to amino acids or protein proteolytic degradation products, fatty acids, or carbohydrates and include receptors such as the calcium-sensing receptor, the G protein-coupled receptor family C, taste receptors, and free fatty acid sensing receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC RELEVANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the control mechanisms of cellular signaling may lead to a number of pathophysiologic consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/18\">",
"     18",
"    </a>",
"    ]. Numerous receptor mutations have been identified that result in unregulated stimulation in the absence of hormone (constitutive activity). As examples, a constitutively active receptor has been found in thyroid adenomas producing clinical hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/19\">",
"     19",
"    </a>",
"    ] and in precocious puberty secondary to a mutation in the luteinizing hormone receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, the McCune-Albright syndrome is due to postzygotic activating mutations in the gene encoding the G alpha s protein, resulting in activation of the signal-transduction pathway generating cyclic AMP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22293/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The clinical manifestations include polyostotic fibrous dysplasia, cafe au lait spots, and hyperfunction of multiple glands that can lead to sexual precocity, Cushing's syndrome, acromegaly, hyperthyroidism, or hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal transduction is a process in which a peptide hormone transfers specific information from the outside of the target cell to exert a cellular response. For this to occur, the hormone exerts a signal through a specific receptor that transmits information from the extracellular compartment into the cell. This message is tightly controlled, especially in settings that are vital for cellular homeostasis (",
"    <a class=\"graphic graphic_figure graphicRef74916 \" href=\"UTD.htm?0/11/190\">",
"     figure 1",
"    </a>",
"    ). With improved understanding of receptor structure using x-ray crystallography and computer modeling, G protein-coupled receptors are becoming more attractive as drug targets.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/1\">",
"      Lefkowitz RJ. G proteins in medicine. N Engl J Med 1995; 332:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/2\">",
"      Krontiris TG. Oncogenes. N Engl J Med 1995; 333:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/3\">",
"      Vaughan M. Signaling by heterotrimeric G proteins minireview series. J Biol Chem 1998; 273:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/4\">",
"      Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/5\">",
"      Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/6\">",
"      Mason JS, Bortolato A, Congreve M, Marshall FH. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci 2012; 33:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/7\">",
"      Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/8\">",
"      Ranganathan R, Stevens CF. Arrestin binding determines the rate of inactivation of the G protein-coupled receptor rhodopsin in vivo. Cell 1995; 81:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/9\">",
"      Ferguson SS, Downey WE 3rd, Colapietro AM, et al. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996; 271:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/10\">",
"      Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005; 308:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/11\">",
"      Ibrahim IA, Kurose H. &beta;-arrestin-mediated signaling improves the efficacy of therapeutics. J Pharmacol Sci 2012; 118:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/12\">",
"      Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/13\">",
"      Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004; 116:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/14\">",
"      Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell 2000; 103:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/15\">",
"      Shi Y, Massagu&eacute; J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/16\">",
"      Wellendorph P, Johansen LD, Br&auml;uner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/17\">",
"      Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal chemosensation. Cell Metab 2012; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/18\">",
"      Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/19\">",
"      Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/20\">",
"      Shenker A, Laue L, Kosugi S, et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/21\">",
"      Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/22\">",
"      Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22293/abstract/23\">",
"      Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3804 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22293=[""].join("\n");
var outline_f21_49_22293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECEPTOR STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      G proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      G protein-coupled receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effector systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adenylate cyclase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Phospholipase C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SIGNAL REGULATION AND TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Internalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Beta-arrestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Non-G protein-coupled receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Receptor tyrosine kinases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Receptor serine/threonine kinases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHYSIOLOGIC NUTRIENT SENSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATHOPHYSIOLOGIC RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/3804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/3804|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/11/190\" title=\"figure 1\">",
"      Peptide hormone binding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/55/19326\" title=\"figure 2\">",
"      Activation of G proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/20/324\" title=\"figure 3\">",
"      G protein structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/62/39918\" title=\"figure 4\">",
"      Effector systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/3804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/51/2875\" title=\"table 1\">",
"      Classification of G proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/42/5803\" title=\"table 2\">",
"      Types of effector systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22294="Anastrozole: Drug information";
var content_f21_49_22294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Anastrozole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18485?source=see_link\">",
"    see \"Anastrozole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arimidex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Anastrozole&reg;;",
"     </li>",
"     <li>",
"      Arimidex&reg;;",
"     </li>",
"     <li>",
"      JAMP-Anastrozole;",
"     </li>",
"     <li>",
"      Mar-Anastrozole;",
"     </li>",
"     <li>",
"      PMS-Anastrozole;",
"     </li>",
"     <li>",
"      Riva-Anastrozole;",
"     </li>",
"     <li>",
"      Sandoz-Anastrozole;",
"     </li>",
"     <li>",
"      Taro-Anastrozole;",
"     </li>",
"     <li>",
"      Teva-Anastrozole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Aromatase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Postmenopausal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, advanced:",
"     </b>",
"     Oral: 1 mg once daily; continue until tumor progression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, early (adjuvant treatment):",
"     </b>",
"     Oral: 1 mg once daily; optimal duration unknown, duration in clinical trial is 5 years",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F135540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustment is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F135541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment or stable hepatic cirrhosis: Dosage adjustment is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Has not been studied in this population.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arimidex&reg;: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6884236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     First-line treatment of locally-advanced or metastatic breast cancer (hormone receptor-positive or unknown) in postmenopausal women; treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy; adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal women",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6884223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of recurrent or metastatic endometrial or uterine cancers, treatment of recurrent ovarian cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6743663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anastrozole may be confused with anagrelide, letrozole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Arimidex&reg; may be confused with Aromasin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilatation (25% to 36%), ischemic cardiovascular disease (4%; 17% in patients with pre-existing ischemic heart disease), hypertension (2% to 13%), angina (2%; 12% in patients with pre-existing ischemic heart disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mood disturbance (19%), fatigue (19%), pain (11% to 17%), headache (9% to 13%), depression (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (12% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11% to 19%), vomiting (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (16% to 19%), arthritis (17%), arthralgia (2% to 15%), back pain (10% to 12%), bone pain (6% to 11%), osteoporosis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (6% to 14%), cough increased (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (5% to 10%), chest pain (5% to 7%), edema (7%), venous thromboembolic events (2% to 4%), ischemic cerebrovascular events (2%), MI (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (2% to 10%), dizziness (6% to 8%), anxiety (2% to 6%), fever (2% to 5%), malaise (2% to 5%), confusion (2% to 5%), nervousness (2% to 5%), somnolence (2% to 5%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (2% to 5%), pruritus (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (9%), breast pain (2% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (8% to 9%), constipation (7% to 9%), abdominal pain (7% to 9%), weight gain (2% to 9%), anorexia (5% to 7%), xerostomia (6%), dyspepsia (7%), weight loss (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 8%), vulvovaginitis (6%), pelvic pain (5%), vaginal bleeding (1% to 5%), vaginitis (4%), vaginal discharge (4%), vaginal hemorrhage (2% to 4%), leukorrhea (2% to 3%), vaginal dryness (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (2% to 5%), leukopenia  (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (1% to 10%), alkaline phosphatase increased (1% to 10%), gamma GT increased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fracture (1% to 10%), arthrosis (7%), paresthesia (5% to 7%), joint disorder (6%), myalgia (2% to 6%), neck pain (2% to 5%), carpal tunnel syndrome (3%), hypertonia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataracts (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (8% to 10%), sinusitis (2% to 6%), bronchitis (2% to 5%), rhinitis (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphedema (10%), infection (2% to 9%), flu-like syndrome (2% to 7%), diaphoresis (2% to 5%), cyst (5%), neoplasm (5%), tumor flare (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, bilirubin increased, CVA, cerebral ischemia, cerebral infarct, cutaneous vasculitis (including Henoch-Sch&ouml;nlein purpura), endometrial cancer, erythema multiforme, hepatitis, jaundice, joint pain, joint stiffness, liver inflammation, liver pain, liver swelling, myocardial ischemia, pulmonary embolus, retinal vein thrombosis; skin reactions (eg, blisters, lesions, ulcers); Stevens-Johnson syndrome, trigger finger, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to anastrozole or any component of the formulation; use in women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Due to decreased circulating estrogen levels, anastrozole is associated with a reduction in bone mineral density (BMD); decreases (from baseline) in total hip and lumbar spine BMD have been reported. Patients with pre-existing osteopenia are at higher risk for developing osteoporosis (Eastell, 2008). When initiating anastrozole treatment, follow available guidelines for bone mineral density management in postmenopausal women with similar fracture risk; concurrent use of bisphosphonates may be useful in patients at risk for fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Elevated total cholesterol levels (contributed to by LDL cholesterol increases) have been reported in patients receiving anastrozole; use with caution in patients with hyperlipidemias. Cholesterol levels should be monitored/managed in accordance with current guidelines for patients with LDL elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Plasma concentrations in patients with stable hepatic cirrhosis were within the range of concentrations seen in normal subjects across all clinical trials. Has not been studied in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disease: Patients with pre-existing ischemic cardiac disease have an increased risk for ischemic cardiovascular events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use is contraindicated in women who are or may become pregnant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal women: Anastrozole offers no clinical benefit in premenopausal women with breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F135567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May decrease the serum concentration of Anastrozole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetotoxicity was observed in animal studies. Anastrozole is contraindicated in women who are or may become pregnant (may cause fetal harm if administered during pregnancy). Use in premenopausal women with breast cancer does not provide any clinical benefit.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9406165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F135518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Anastrozole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $404.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Arimidex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $520.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1878921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone mineral density; total cholesterol and LDL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F135520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Dex (KP);",
"     </li>",
"     <li>",
"      Altraz (IN);",
"     </li>",
"     <li>",
"      Anaccord (NZ);",
"     </li>",
"     <li>",
"      Anatrole (NZ);",
"     </li>",
"     <li>",
"      Anazo (TW);",
"     </li>",
"     <li>",
"      Anzol (PH);",
"     </li>",
"     <li>",
"      Aremed (TH, TW);",
"     </li>",
"     <li>",
"      Aremed 1 (SG);",
"     </li>",
"     <li>",
"      Arimidex (AR, AT, AU, BB, BD, BE, BF, BG, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IT, JM, JP, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RU, SC, SD, SE, SG, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Astrozol (PH);",
"     </li>",
"     <li>",
"      Atrozole (KP);",
"     </li>",
"     <li>",
"      Femizet (TH);",
"     </li>",
"     <li>",
"      Trozolet (CN, EC, PY, UY, VE);",
"     </li>",
"     <li>",
"      Trozolite (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of estradiol reduction: 70% reduction after 24 hours; 80% after 2 weeks therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of estradiol reduction: 6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; extent of absorption not affected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (~85%) via N-dealkylation, hydroxylation, and glucuronidation; primary metabolite (triazole) inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~2 hours without food; 5 hours with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (urinary excretion accounts for ~10% of total elimination, mostly as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Prestrud AA, Seidenfeld J, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(23):3784-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/20625130/pubmed\" id=\"20625130\" target=\"_blank\">",
"        20625130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar AU, Robertson JF, Eiermann W, et al, &ldquo;An Overview of the Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors Anastrozole, Letrozole, and Exemestane,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(9):2006-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/12404296/pubmed\" id=\"12404296\" target=\"_blank\">",
"        12404296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuzick J, Sestak I, Baum M, et al, &ldquo;Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(12):1135-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/ 21087898/pubmed\" id=\" 21087898\" target=\"_blank\">",
"        21087898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      del Carmen MG, Fuller AF, Matulonis U, et al, &ldquo;Phase II Trial of Anastrozole in Women With Asymptomatic M&uuml;llerian Cancer,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2003, 91(3):596-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/14675683/pubmed\" id=\"14675683\" target=\"_blank\">",
"        14675683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eastell R, Adams JE, Coleman RE, et al, &ldquo;Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(7):1051-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/18309940/pubmed\" id=\"18309940\" target=\"_blank\">",
"        18309940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JF, Cuzick J, Buzdar A, et al, &ldquo;Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-month Analysis of the ATAC Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2008, 9(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/18083636/pubmed\" id=\"18083636\" target=\"_blank\">",
"        18083636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenkins VA, Ambroisine LM, Atkins L, et al, &ldquo;Effects of Anastrozole on Cognitive Performance in Postmenopausal Women: A Randomised, Double-Blind Chemoprevention Trial (IBIS II),&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2008, 9(10):953-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/18768369/pubmed\" id=\"18768369\" target=\"_blank\">",
"        18768369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufmann M, Jonat W, Hilfrich J, et al, &ldquo;Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2664-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/17563395/pubmed\" id=\"17563395\" target=\"_blank\">",
"        17563395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kendall A, Dowsett M, Folkerd E, et al, &ldquo;Caution: Vaginal Estradiol Appears to be Contraindicated in Postmenopausal Women on Adjuvant Aromatase Inhibitors,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(4):584-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/16443612/pubmed\" id=\"16443612\" target=\"_blank\">",
"        16443612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koberle D and Thurlimann B, &ldquo;Anastrozole: Pharmacological and Clinical Profile in Postmenopausal Women With Breast Cancer,&rdquo;",
"      <i>",
"       Expert Rev Anticancer Ther",
"      </i>",
"      , 2001, 1(2):169-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/12113022/pubmed\" id=\"12113022\" target=\"_blank\">",
"        12113022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lester JE, Dodwell D, Purohit OP, et al, &ldquo;Prevention of Anastrozole-Induced Bone Loss With Monthly Oral Ibandronate During Adjuvant Aromatase Inhibitor Therapy for Breast Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2008, 14(19):6336-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/18829518/pubmed\" id=\"18829518\" target=\"_blank\">",
"        18829518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lonning PE, Geisler J, and Dowsett M, &ldquo;Pharmacological and Clinical Profile of Anastrozole,&rdquo;",
"      <i>",
"       Breast Cancer Res Treat",
"      </i>",
"      , 1998, 49(Suppl 1):53-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lonning P, Pfister C, Martoni A, et al, &ldquo;Pharmacokinetics of Third-Generation Aromatase Inhibitors,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(4 Suppl 14):23-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/14513434/pubmed\" id=\"14513434\" target=\"_blank\">",
"        14513434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Ovarian Cancer,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Uterine Neoplasms,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician's Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at  file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Njar VC and Brodie AM, &ldquo;Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1999, 58(2):233-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/10473018/pubmed\" id=\"10473018\" target=\"_blank\">",
"        10473018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose PG, Brunetto VL, VanLe L, et al, &ldquo;A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2000, 78(2):212-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/10926805/pubmed\" id=\"10926805\" target=\"_blank\">",
"        10926805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(25):3143-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/12485966/pubmed\" id=\"12485966\" target=\"_blank\">",
"        12485966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winer EP, Hudis C, Burstein HJ, et al, &ldquo;American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(3):619-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22294/abstract-text/15545664/pubmed\" id=\"15545664\" target=\"_blank\">",
"        15545664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8780 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22294=[""].join("\n");
var outline_f21_49_22294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135534\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135535\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135573\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135538\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135539\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135540\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135541\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135497\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884236\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884223\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743663\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135571\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135516\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135501\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135567\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135506\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135508\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135545\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406165\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135518\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1878921\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135520\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135500\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135515\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18485?source=related_link\">",
"      Anastrozole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22295="Nisoldipine: Drug information";
var content_f21_49_22295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nisoldipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/46/31460?source=see_link\">",
"    see \"Nisoldipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sular&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sular&reg; (Geomatrix&reg; delivery system):",
"     </b>",
"     Oral: Initial: 17 mg once daily, then increase by 8.5 mg/week (or longer intervals) to attain adequate control of blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Usual dose range:",
"     </i>",
"     17-34 mg once daily; doses &gt;34 mg once daily are not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nisoldipine extended-release tablet (original formulation):",
"     </b>",
"     Initial: 20 mg once daily, then increase by 10 mg/week (or longer intervals) to attain adequate control of blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Usual dose range (JNC 7):",
"     </i>",
"     10-40 mg once daily; doses &gt;60 mg once daily are not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Conversion from nisoldipine extended-release (original formulation) to Sular&reg; Geomatrix&reg; delivery system:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Nisoldipine Extended Release Dosing Equivalency",
"     </caption>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Original Extended Release Formulation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Sular&reg; Extended Release (Geomatrix&reg; delivery system)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.5 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25.5 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         34 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sular&reg; (Geomatrix&reg; delivery system): Initial dose: 8.5 mg once daily; increase by 8.5 mg/week (or longer intervals) to attain adequate blood pressure control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine extended-release (original formulation): Initial dose: 10 mg once daily; increase by 10 mg/week (or longer intervals) to attain adequate blood pressure control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Conversion from nisoldipine extended-release (original formulation) to Sular&reg; Geomatrix&reg; delivery system: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F201820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sular&reg; (Geomatrix&reg; delivery system): An initial dose exceeding 8.5 mg once daily is not recommended for patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Nisoldipine extended-release (original formulation): An initial dose exceeding 10 mg once daily is not recommended for patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 8.5 mg, 17 mg, 25.5 mg, 34 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sular&reg;: 8.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sular&reg;: 17 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sular&reg;: 25.5 mg [DSC], 34 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral [original formula]: 20 mg, 30 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day to ensure minimal fluctuation of serum levels. Avoid high-fat diet. Administer on an empty stomach (1 hour before or 2 hours after a meal). Swallow whole; do not crush, break, split, or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension, alone or in combination with other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nisoldipine may be confused with NIFEdipine, niMODipine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (dose related; 7% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (4%), palpitation (3%), angina exacerbation (2%), chest pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (5%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, amblyopia, amnesia, anemia, anorexia, anxiety, appetite increased, arthralgia, arthritis, asthma, ataxia, atrial fibrillation, blepharitis, BUN increased, bruising, cellulitis, cerebral ischemia, colitis, conjunctivitis, creatinine increased, creatine kinase increased, CVA, depression, diabetes mellitus, diaphoresis, diarrhea, dreams abnormal, dyspepsia, dysphagia, dyspnea, dysuria, end inspiratory wheeze, epistaxis, exfoliative dermatitis, facial edema, fever, first-degree AV block, flu-like syndrome, gastritis, gastrointestinal hemorrhage, gingival hyperplasia, glaucoma, glossitis, gout, gynecomastia, heart failure (decompensated), hematuria, hepatomegaly, herpes simplex, herpes zoster; hypersensitivity reaction (eg, angioedema, shortness of breath, tachycardia, chest tightness, hypotension, and rash); hyper-/hypotension, hypertonia, hypoesthesia, hypokalemia, insomnia, jugular venous distention, keratoconjunctivitis, leukopenia, libido decreased, liver function tests abnormal, maculopapular rash, malaise, melena, migraine, mouth ulceration, myalgia, myasthenia, MI, myositis, nocturia, nonprotein nitrogen increased, orthostatic hypotension, paresthesia, petechiae, photosensitivity, pleural effusion, pruritus, pustular rash, rales, retinal detachment, skin discoloration, skin ulcer, somnolence, supraventricular tachycardia, syncope, systolic ejection murmur, taste disturbance, temporary unilateral loss of vision, tenosynovitis, thyroiditis, tremor; T-wave abnormalities on ECG (flattening, inversion, nonspecific changes); urinary frequency, urticaria, vaginal hemorrhage, venous insufficiency, ventricular extrasystoles, vertigo, vitreous floater, weight gain/loss, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nisoldipine, any component of the formulation, or other dihydropyridine calcium channel blockers",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Monitor closely during initial dosing and with dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF; safety and efficacy has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; lower starting dose required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some dosage forms contain tartrazine, which may cause allergic reactions in certain individuals (eg, aspirin hypersensitivity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &gt;65 years of age; lower starting dose recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak concentrations of nisoldipine may be significantly increased if taken with high-lipid foods; however, total exposure (AUC) may be reduced. Grapefruit juice has been shown to significantly increase the bioavailability of nisoldipine. Management: Take on an empty stomach 1 hour before or 2 hours after a meal. Avoid a high-fat diet. Avoid grapefruit products before and after dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease nisoldipine levels. Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of nisoldipine (eg, shepherd's purse). Management: Avoid St John's wort. Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6063538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated fetotoxic but not teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6063542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach (1 hour before or 2 hours after a meal). Avoid grapefruit juice before and after dosing. Avoid grapefuit juice; avoid high-fat diet.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Nisoldipine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5 mg (100): $614.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17 mg (100): $769.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $923.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25.5 mg (100): $839.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $1007.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     34 mg (100): $839.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $1007.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Sular Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.5 mg (100): $1417.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17 mg (100): $1417.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     34 mg (100): $1417.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6063543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angiolat (UY);",
"     </li>",
"     <li>",
"      Baymycard (BG, DE, HN, HU, JP);",
"     </li>",
"     <li>",
"      Corasol (CN);",
"     </li>",
"     <li>",
"      Nisodipen (AR);",
"     </li>",
"     <li>",
"      Nisoldin (KP);",
"     </li>",
"     <li>",
"      Syscor (AT, BE, CH, ES, FI, GR, IT, LU, NL, NZ, PL, TW);",
"     </li>",
"     <li>",
"      Syscor AP (BR);",
"     </li>",
"     <li>",
"      Syscor CC (BB, BM, BS, BZ, GY, JM, NL, NZ, SR, TT);",
"     </li>",
"     <li>",
"      Syscor ER (KP);",
"     </li>",
"     <li>",
"      Syscor MR (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a dihydropyridine calcium channel blocker, structurally similar to nifedipine, nisoldipine impedes the movement of calcium ions into vascular smooth muscle and cardiac muscle. Dihydropyridines are potent vasodilators and are not as likely to suppress cardiac contractility and slow cardiac conduction as other calcium antagonists such as verapamil and diltiazem; nisoldipine is 5-10 times as potent a vasodilator as nifedipine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed. Peak concentrations significantly increased with high-lipid meals; however, AUC is reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; 1 active metabolite (10% of activity of parent); first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 4-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 80% as inactive metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22295/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2000, 36(3):970-1062.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22295/abstract-text/10987629/pubmed\" id=\"10987629\" target=\"_blank\">",
"        10987629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22295/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Estacio RO, Jeffers BW, Hiatt WR, et al, &ldquo;The Effect of Nisoldipine as Compared With Enalapril on Cardiovascular Outcomes in Patients With Noninsulin-Dependent Diabetes and Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(10):645-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22295/abstract-text/9486993/pubmed\" id=\"9486993\" target=\"_blank\">",
"        9486993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22295/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9703 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22295=[""].join("\n");
var outline_f21_49_22295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201814\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201818\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201819\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201820\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201793\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201797\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201796\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201852\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201843\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201800\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201784\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201839\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201811\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201790\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063538\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201823\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063542\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201802\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063543\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201803\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201783\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201799\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9703|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/46/31460?source=related_link\">",
"      Nisoldipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22296="Methadone: Pediatric drug information";
var content_f21_49_22296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methadone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"    see \"Methadone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/13/4310?source=see_link\">",
"    see \"Methadone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dolophine&reg;;",
"     </li>",
"     <li>",
"      Methadone Diskets&reg;;",
"     </li>",
"     <li>",
"      Methadone Intensol&trade;;",
"     </li>",
"     <li>",
"      Methadose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metadol-D&trade;;",
"     </li>",
"     <li>",
"      Metadol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be titrated to appropriate effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neonatal abstinence syndrome (opioid withdrawal):",
"     </b>",
"     Oral, I.V.: Initial: 0.05-0.2 mg/kg/dose given every 12-24 hours or 0.5 mg/kg/day divided every 8 hours; individualize dose and tapering schedule to control symptoms of withdrawal; usually taper dose by 10% to 20% per week over 1 to 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     months (AAP, 1998).",
"     <b>",
"      Note",
"     </b>",
"     : Due to long elimination half-life, tapering is difficult; consider alternate agent.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"      see \"Methadone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be titrated to appropriate effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosing interval may range from 4-12 hours during initial therapy; decrease in dose or frequency may be required (&sim;2-5 days after initiation of therapy or dosage increase) due to accumulation with repeated doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: 0.1 mg/kg/dose every 4 hours for 2-3 doses, then every 6-12 hours as needed; maximum dose: 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, I.M., SubQ: Initial: 0.1 mg/kg/dose every 4 hours for 2-3 doses, then every 6-12 hours as needed or 0.7 mg/kg/24 hours divided every 4-6 hours as needed; maximum dose: 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Iatrogenic opioid dependency:",
"     </b>",
"     Oral: Controlled studies have not been conducted; several clinically used dosing regimens have been reported. Methadone dose",
"     <b>",
"      must be individualized",
"     </b>",
"     and will depend upon patient's previous opioid dose and severity of opioid withdrawal; patients who have received higher doses of opioids will require higher methadone doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     General guidelines: Initial: 0.05-0.1 mg/kg/dose every 6 hours; increase by 0.05 mg/kg/dose until withdrawal symptoms are controlled; after 24-48 hours, the dosing interval can be lengthened to every 12-24 hours; to taper dose, wean by 0.05 mg/kg/day; if withdrawal symptoms recur, taper at a slower rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Initial 5-10 mg; dosing interval may range from 4-12 hours during initial therapy; decrease in dose or frequency may be required (&sim;2-5 days after initiation of therapy or dosage increase) due to accumulation with repeated doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's recommendations: 2.5-10 mg every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Manufacturer's recommendations: Opioid-naive patients: Initial: 2.5-10 mg every 8-12 hours; titrate slowly to effect; may also be administered by SubQ or I.M. injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Detoxification:",
"     </b>",
"     Oral: 15-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Maintenance of opiate dependence:",
"     </b>",
"     Oral: 20-120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% to 75% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [concentrate]: 10 mg/mL (946 mL, 1000 mL, 1000s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadone Intensol&trade;: 10 mg/mL (30 mL) [dye free, sugar free; contains sodium benzoate; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 10 mg/mL (1000 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 10 mg/mL (1000 mL) [dye free, sugar free; contains sodium benzoate; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dolophine&reg;: 5 mg, 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, dispersible, oral, as hydrochloride: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadone Diskets&reg;: 40 mg [scored; orange-pineapple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methadose&reg;: 40 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     When used for treatment of opioid addiction: May only be dispensed in accordance to guidelines established by the Substance Abuse and Mental Health Services Administration&rsquo;s (SAMHSA) Center for Substance Abuse Treatment (CSAT). Regulations regarding methadone use may vary by state and/or country. Obtain advice from appropriate regulatory agencies and/or consult with pain management/palliative care specialists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Regulatory Exceptions to the General Requirement to Provide Opioid Agonist Treatment (per manufacturer's labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1. During inpatient care, when the patient was admitted for any condition other than concurrent opioid addiction, to facilitate the treatment of the primary admitting diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2. During an emergency period of no longer than 3 days while definitive care for the addiction is being sought in an appropriately licensed facility.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14624980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dolophine&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311370.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM311370.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with juice or water; dispersible tablet should be completely dissolved before administration; oral dose for detoxification and maintenance may be administered in Tang&reg;, Kool-Aid&reg;, apple juice, grape Crystal Light&reg;",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Atropine, dexamethasone sodium phosphate, diazepam, diphenhydramine, haloperidol, hydroxyzine, ketorolac, lorazepam, methotrimeprazine, metoclopramide, midazolam, phenobarbital, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Phenytoin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Protect from moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate to severe pain unresponsive to non-narcotics; used in narcotic detoxification maintenance programs and for the treatment of iatrogenic narcotic dependency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methadone may be confused with dexmethylphenidate, Mephyton&reg;, methylphenidate, Metadate CD&reg;, Metadate&reg; ER, metolazone, morphine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     During prolonged administration, adverse effects may decrease over several weeks; however, constipation and sweating may persist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bigeminal rhythms, bradycardia, cardiac arrest, cardiomyopathy, ECG changes, edema, extrasystoles, faintness, flushing, heart failure, hypotension, palpitation,peripheral vasodilation, phlebitis, orthostatic hypotension, QT interval prolonged, shock, syncope, tachycardia, torsade de pointes, T-wave inversion, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, disorientation, dizziness, drowsiness, dysphoria, euphoria, hallucination, headache, insomnia,  lightheadedness, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hemorrhagic urticaria, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic effect, amenorrhea, hypokalemia, hypomagnesemia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, biliary tract spasm, constipation, glossitis, nausea, stomach cramps, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary retention or hesitancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (reversible, reported in patients with chronic hepatitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: I.M./SubQ injection: Erythema, pain, swelling; I.V. injection: Hemorrhagic urticaria (rare),  pruritus, urticaria, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema, respiratory depression, respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Death, diaphoresis, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methadone or any component; severe respiratory depression (in absence of resuscitative equipment or ventilatory support); acute or severe asthma; hypercarbia; known or suspected ileus",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the cumulative effects of methadone, the dose and frequency of administration need to be reduced with repeated use; use with caution in patients with hepatic, renal, pulmonary, or cardiovascular disease; use with caution and decrease dose in patients who are debilitated and those with severe renal or hepatic dysfunction, hypothyroidism, Addison's disease, urethral stricture, or prostatic hypertrophy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Death and life-threatening adverse events (eg, respiratory depression, cardiac arrhythmias) in patients receiving methadone for pain control have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events may be the result of unintentional overdoses, drug interactions, and cardiac toxicities associated with methadone (QT prolongation, torsade de pointes). Particular vigilance and patient monitoring is necessary during treatment initiation (including conversion from another opioid) and dose titration. Incomplete cross-tolerance between methadone and other opioids may occur; fatalities have been reported when converting patients from chronic, high dose treatment with other opioids to methadone; knowledge of the pharmacokinetics of methadone is essential for appropriate conversion from other opioids (see package insert for conversion tables). Methadone&rsquo;s elimination half-life is significantly longer than its duration of analgesic action. The respiratory depressant effects of methadone occur later and persist longer than its peak analgesic effects. Carefully select initial methadone dose for pain control and slowly titrate to analgesic effect in all patients, including those who are opioid-tolerant. Instruct patients to take methadone as prescribed; do not take more methadone than prescribed without first talking with physician.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Methadone may cause prolongation of the QT interval or torsade de pointes (especially at higher doses, eg, in adults with doses &gt;200 mg/day)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients at risk for QT prolongation (eg, patients with cardiac hypertrophy, hypokalemia, hypomagnesemia, concomitant diuretic use), with medications known to prolong the QT interval, or with history of conduction abnormalities. Monitoring of the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prior to and during therapy has been recommended by the Center for Substance Abuse and Treatment (CSAT).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause respiratory depression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with extreme caution in patients with respiratory disease or pre-existing respiratory depression; methadone's effect on respiration lasts longer than analgesic effects. Use with extreme caution (and only if essential) in patients with head injury, increased ICP, or other intracranial lesions. May cause severe hypotension; use with caution in patients with severe volume depletion or circulatory shock. Tablets are to be used only for oral administration and",
"     <b>",
"      must not",
"     </b>",
"     be used for injection. Abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concentrated oral solution may contain propylene glycol or sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; avoid use of methadone products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Methadone. Boceprevir may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Methadone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Methadone may decrease the serum concentration of Didanosine.  Management: If use of methadone with didanosine is necessary, enteric coated didanosine is preferred.  Avoid using didanosine powder for solution with methadone.  Increased monitoring of clinical response to didanosine (including viral load) is necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with fluconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with ketoconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Methadone. Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the QTc-prolonging effect of Methadone. Posaconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Methadone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atazanavir; Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the metabolism of Methadone. Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Delavirdine; Etravirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Methadone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Methadone. Management: Methadone dose reduction may be necessary when used with voriconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Methadone may increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some, but not all, animal studies. Data collected by the Teratogen Information System are complicated by maternal use of illicit drugs, nutrition, infection, and psychosocial circumstances. However, pregnant women in methadone treatment programs are reported to have improved fetal outcomes compared to pregnant women using illicit drugs. Methadone can be detected in the amniotic fluid, cord plasma, and newborn urine. Fetal growth, birth weight, length, and/or head circumference may be decreased in infants born to narcotic-addicted mothers treated with methadone during pregnancy. Growth deficits do not appear to persist; however, decreased performance on psychometric and behavioral tests has been found to continue into childhood. Abnormal fetal nonstress tests have also been reported. Withdrawal symptoms in the neonate may be observed up to 2-4 weeks after delivery. The manufacturer states that methadone should be used during pregnancy only if clearly needed. Because methadone clearance in pregnant women is increased and half-life is decreased during the 2nd and 3rd trimesters of pregnancy, withdrawal symptoms may be observed in the mother; dosage of methadone may need increased or dosing interval decreased during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory, cardiovascular, and mental status, pain relief (if used for analgesia), abstinence scoring system (if used for neonatal abstinence syndrome); ECG for monitoring QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prior to and during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parenteral: Within 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Parenteral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 6-8 hours; after repeated doses, duration increases to 22-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : (Mean &plusmn; SD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 7.1 &plusmn; 2.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 6.1 &plusmn; 2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 2-6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90% (primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: N-demethylated in the liver to an inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: May be prolonged with alkaline pH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 19 &plusmn; 14 hours (range: 4-62 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 35 &plusmn; 22 hours (range: 9-87 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (&lt;10% as unchanged drug); increased renal excretion with urine pH &lt;6;",
"     <b>",
"      Note:",
"     </b>",
"     Methadone may persist in the liver and other tissues; slow release from tissues may prolong the pharmacologic effect despite low serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis, peritoneal dialysis: Not established as effective for increasing the elimination of methadone (or metabolite)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/13/4310?source=see_link\">",
"      see \"Methadone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may be habit-forming; avoid abrupt discontinuation after prolonged use; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension (use with caution when changing positions from lying or sitting to standing); seek medical attention immediately if you experience heart palpitations, dizziness, lightheadedness, or fainting (these may be symptoms of an arrhythmia)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methadone accumulates with repeated doses and dosage may need to be adjusted downward after 3-5 days to prevent toxic effects. Some patients may benefit from every 8- to 12-hour dosing interval (pain control).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Methadone 10 mg I.M. = morphine 10 mg I.M.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Center for Substance Abuse and Treatment (CSAT) of the Substance Abuse and Mental Health Services Administration has developed a consensus guideline statement outlining recommendations regarding ECG monitoring in patients being considered for and being treated with methadone regardless of indication. Of note, these recommendations should not supersede clinical judgment or patient preferences and may not apply to patients with terminal, intractable cancer pain. Five recommendations have been developed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Recommendation 1: Disclosure: Clinicians should inform patients of arrhythmia risk when methadone is prescribed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Recommendation 2: Clinical History: Clinicians should inquire about any history of structural heart disease, arrhythmia, and syncope.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Recommendation 3: Screening: Clinicians should obtain pretreatment ECG for all patients to measure QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, follow up ECG within 30 days, then annually (monitor more frequently if patient receiving &gt;100 mg/day or if unexplained syncope or seizure occurs while on methadone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Recommendation 4: Risk Stratification: If before or at anytime during therapy the",
"     <i>",
"      QT",
"      <sub>",
"       c",
"      </sub>",
"      &gt;450-499 msecs",
"     </i>",
"     : Discuss potential risks and benefits; monitor QT",
"     <sub>",
"      c",
"     </sub>",
"     more frequently. If before or anytime during therapy the",
"     <i>",
"      QT",
"      <sub>",
"       c",
"      </sub>",
"      &ge;500 msecs",
"     </i>",
"     : Consider discontinuation or reducing methadone dose or eliminate factors promoting QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (eg, potassium-wasting drugs) or use alternative therapy (eg, buprenorphine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Recommendation 5: Drug Interactions: Clinicians should be aware of interactions between methadone and other drugs that either prolong the QT interval or reduce methadone elimination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The panel also concluded that the arrhythmia risk is directly associated with methadone's ability to block the delayed rectifier potassium channel (Ikr) and prolong repolarization. The guideline further states that the use of the Bazett formula is adequate even though it is likely to overcorrect with high heart rates. The patient should remain supine for at least 5 minutes prior to obtaining ECG. In addition, screening for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation using automated readings does not require a specialist (eg, cardiologist) and may be performed in a primary care setting. However, in cases when uncertainty exists about whether or not clinically significant QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation is present, the ECG should be repeated or interpreted by a cardiologist. For more information, Krantz, 2009.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Neonatal Drug Withdrawal,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(6):1079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/9614425/pubmed\" id=\"9614425\" target=\"_blank\">",
"        9614425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anand KJ and Arnold JH, &ldquo;Opioid Tolerance and Dependence in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(2):334-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/8306694/pubmed\" id=\"8306694\" target=\"_blank\">",
"        8306694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krantz MJ, Lewkowiez L, Hays H, et al, &ldquo;Torsade de Pointes Associated With Very-High-Dose Methadone,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2002, 137(6):501-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/12230351/pubmed\" id=\"12230351\" target=\"_blank\">",
"        12230351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krantz MJ, Martin J, Stimmel B, et al, \"QT",
"      <sub>",
"       c",
"      </sub>",
"      Interval Screening in Methadone Treatment,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(6):387-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/19153406/pubmed\" id=\"19153406\" target=\"_blank\">",
"        19153406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauriault G, LeBelle MJ, Lodge BA, et al, &ldquo;Stability of Methadone in Four Vehicles for Oral Administration,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1991, 48(6):1252-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/1858805/pubmed\" id=\"1858805\" target=\"_blank\">",
"        1858805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/49/22296/abstract-text/7614777 /pubmed\" id=\"7614777 \" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12590 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22296=[""].join("\n");
var outline_f21_49_22296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709037\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053862\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443863\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053855\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194038\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234073\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14624980\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053867\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194044\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053858\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053866\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194046\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194043\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053871\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053854\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053853\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194032\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053861\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053852\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053869\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053870\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053860\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053872\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=related_link\">",
"      Methadone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/13/4310?source=related_link\">",
"      Methadone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22297="Surgery for native valve endocarditis";
var content_f21_49_22297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery for native valve endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/49/22297/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/49/22297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery was not an option in the management of infective endocarditis (IE) until 1961 when Kay and colleagues excised fungal vegetations from the tricuspid valve of a patient with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/1\">",
"     1",
"    </a>",
"    ]. This was followed by a report in 1965 in which an aortic valve was successfully replaced in a patient with active endocarditis due to Serratia marcescens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/2\">",
"     2",
"    </a>",
"    ]. During the last three decades, valve replacement and even valve repair have become commonplace in the management of selected complications of IE, and a reduction in mortality from IE has been ascribed to the combination of antibiotic therapy and timely surgical intervention.",
"   </p>",
"   <p>",
"    The efficacy, indications for, and outcomes of surgery in native valve endocarditis will be reviewed here. The medical treatment of native valve endocarditis and the role of surgery in prosthetic valve endocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for the role of surgery has been evaluated in observational and retrospective studies limited by confounding factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The following observational studies are representative of the data suggesting benefit of surgery in selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 513 patients with complicated native valve endocarditis between 1990 and 2000, valve surgery was associated with reduced mortality at six months, whether the analysis was unadjusted, corrected for variation in baseline characteristics, or adjusted by propensity matching [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. On propensity analysis in 218 patients, surgery was associated with a significant reduction in mortality (15 versus 28 percent without surgery, hazard ratio 0.45, 95% CI 0.23-0.86). The reduction in mortality was greatest in patients with moderate to severe heart failure (14 versus 51 percent, hazard ratio 0.22, 95% CI 0.09-0.53). There was no significant benefit in patients with no or only mild heart failure.",
"     </li>",
"     <li>",
"      In a longitudinal prospective cohort study of 333 patients with left sided IE (75 percent with native valve involvement) between 1996 and 2002, a propensity matching score was used to identify two groups including 51 patients; one received medical therapy and underwent early surgical treatment and one received medical therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/5\">",
"       5",
"      </a>",
"      ]. Regression analysis demonstrated that surgery was associated with a decreased likelihood of death (hazard ratio, 0.27; 95% CI 0.31-0.55). The difference was greatest in patients with moderate to severe heart failure. A survival benefit with surgery was only observed after 40 days; before that time, there was likely a balance between the risk of acute IE and the risk of surgery. Independent predictors of worse long-term survival included diabetes, chronic indwelling central catheter at diagnosis, and perivalvular complications.",
"     </li>",
"     <li>",
"      In a propensity analysis of a cohort including 1552 patients with native valve endocarditis, early surgery (defined as surgery during the initial hospitalization for IE) was associated with a 5.9 percent absolute risk reduction after propensity-based matching and adjustment for survivor bias. Subgroup analysis demonstrated a similar positive benefit for early surgery among patients with perivalvular complications, systemic embolization and infection due to S. aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in a retrospective analysis of 546 patients with IE, surgery for left sided IE did not improve six-month survival; both propensity matching and consideration of the timing of surgery were taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/7\">",
"     7",
"    </a>",
"    ]. No survival benefit for surgery was observed, and a trend toward increased six-month mortality was noted.",
"   </p>",
"   <p>",
"    The general consensus of most experienced clinicians remains that heart failure, particularly if moderate to severe, is a definite indication for surgery in a patient with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for surgery have expanded over time; in general, valve replacement surgery has gradually been performed progressively earlier in the course of illness. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations for surgery in patients with native valve endocarditis (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9\">",
"     9",
"    </a>",
"    ]. The European Society of Clinical Microbiology and Infectious Diseases published guidelines for the prevention and treatment of infective endocarditis in 2009 (",
"    <a class=\"graphic graphic_table graphicRef67774 \" href=\"UTD.htm?11/6/11373\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/10\">",
"     10",
"    </a>",
"    ]. The indications for surgery in these guidelines closely mirror the American guidelines.",
"   </p>",
"   <p>",
"    There is a general consensus that surgery is warranted for patients with active native valve IE who have one or more of the following complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure (HF), particularly if moderate to severe, that is directly related to valve dysfunction.",
"     </li>",
"     <li>",
"      Severe aortic or mitral regurgitation with evidence of abnormal hemodynamics such as premature closure of the mitral valve in patients with aortic insufficiency.",
"     </li>",
"     <li>",
"      Endocarditis due to fungal or other highly resistant organisms",
"     </li>",
"     <li>",
"      Perivalvular infection with abscess or fistula formation",
"     </li>",
"     <li>",
"      Several other complications are considered possible indications for surgery in selected patients with IE. These possible indications are reviewed in more detail below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the routine use of valve replacement or valve repair, heart failure (HF) caused approximately 90 percent of deaths in patients with IE. Moderate to severe HF caused by IE confers a high mortality risk without corrective surgery. As discussed above, medical therapy alone is associated with mortality rates of approximately 75 percent; this can be reduced to 25 percent or less with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with IE who undergo surgery, HF is the indication for surgery in two-thirds to three-fourths of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/15\">",
"     15",
"    </a>",
"    ]. In general, endocarditis-induced aortic regurgitation is more likely to produce HF than endocarditis-induced mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/16\">",
"     16",
"    </a>",
"    ]. Regardless of the valve involved, surgery should be undertaken as soon as signs of moderate or severe HF appear, before extreme or refractory hemodynamic deterioration occurs; it is dangerous in such patients to wait for improvement to occur with medical therapy.",
"   </p>",
"   <p>",
"    Support for this approach comes from a prospective multicenter observational study including 1359 patients with IE and HF in which surgery was performed in only 62 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/17\">",
"     17",
"    </a>",
"    ]. Both the in-hospital and one-year mortality were significantly lower among patients who underwent surgery than patients who did not undergo surgery (21 versus 45 percent and 29 versus 58 percent, respectively). A risk-adjusted analysis found that valvular surgery during the initial hospitalization was independently associated with lower mortality.",
"   </p>",
"   <p>",
"    The activity of the endocarditis (ie, adequately treated versus partially-treated versus inadequately treated) should play a minor role in the decision-making process about surgery in patients with IE and HF. It is the degree of hemodynamic stability that should be the prime determinant for deciding on the timing of surgical intervention. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Timing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The duration of signs and symptoms of HF has an effect on prognosis. In a series of 125 patients with IE published in 1977, the overall prevalence of HF was 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/18\">",
"     18",
"    </a>",
"    ]. The mortality rate was 59 percent in patients with IE and HF of recent onset compared with 39 percent in patients with pre-existing and worsening HF. HF was present in 91 percent of the patients who died.",
"   </p>",
"   <p>",
"    Death may occur suddenly in patients with endocarditis-induced HF, particularly if the aortic valve is involved. In one report of patients with IE and acute aortic regurgitation, 7 of 11 patients with mild HF and 7 of 8 with moderate to severe HF died suddenly during attempted medical therapy; in contrast, only one of five patients with moderately severe HF who underwent surgery died [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although surgery is indicated for clinical evidence of HF in IE, there are a few caveats that need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of noncardiac factors, such as fever, anemia, sepsis, and renal insufficiency may exaggerate the manifestations of HF; as a result, caution must be exercised when these factors are present. In addition, patients with a history of antecedent left ventricular dysfunction may present with signs or symptoms of failure that are out of proportion to the degree of valvular dysfunction. These patients require careful evaluation for extenuating features, followed by standard initial management with diuretics and vasodilators, surgical consultation, and close surveillance of the response to therapy.",
"     </li>",
"     <li>",
"      Severe mitral or aortic regurgitation due to endocarditis is almost always associated with heart failure and early surgical intervention is generally advisable in such patients. Some patients with pre-existing compensated valvular regurgitation become uncompensated because infection results in progressively worsening valve damage and further regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/19\">",
"       19",
"      </a>",
"      ]. Because acute, severe aortic regurgitation is more difficult to manage than mitral regurgitation, more aggressive surgical treatment of patients with aortic insufficiency has been advocated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Asymptomatic severe valvular regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although urgent surgery is not generally required for patients with severe valvular regurgitation without heart failure, some patients without overt heart failure may benefit from early surgery. Individuals with severe regurgitation based on quantitative parameters and evidence of hemodynamic compromise, such as an elevated left ventricular end-diastolic pressure (based upon echocardiographic findings) or evidence for elevated pressure within the pulmonary circulation, may be candidates for early surgery (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77111 \" href=\"UTD.htm?34/46/35564\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complicated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated infection is present when there are persistently positive blood cultures, echocardiographic evidence of perivalvular abscess, leaflet perforation or fistula formation, and in most patients with new heart block.",
"   </p>",
"   <p>",
"    Persistently positive blood cultures after five to seven days or lack of improvement in clinical symptoms after one week of appropriate antibiotic therapy is generally an indication for surgery. A search for a metastatic abscess should be undertaken in such patients before sending them to the operating room.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is recommended to assess the severity of valve dysfunction and to detect perivalvular infection. Evidence of perivalvular infection including abscess, sinus of Valsalva aneurysm, or fistula formation is generally an indication for surgical intervention. Close follow-up (by serial TEE) and earlier surgical intervention in the presence of known difficult-to-treat organisms may decrease the significantly added morbidity of surgical intervention in the presence of perivalvular abscess formation.",
"   </p>",
"   <p>",
"    Surgical intervention is also indicated for most patients with culture-negative endocarditis who exhibit evidence of persistent uncontrolled infection (eg, fever persisting for more than seven to ten days) without evidence of infection at another site. Such patients should also have further imaging studies in an attempt to identify perivalvular infection prior to undergoing surgery.",
"   </p>",
"   <p>",
"    Characterization of the infecting organism is helpful in assessing the likelihood of response to treatment. Fungal endocarditis, for example, is unlikely to respond to medical therapy alone, and early surgical intervention is recommended for patients who are deemed to be suitable for surgery after a diagnosis of fungal endocarditis has been confirmed.",
"   </p>",
"   <p>",
"    Relapse of patients with native valve endocarditis after adequate therapy may require surgical intervention, although a second course of antibiotics may be reasonable if there is no evidence of perivalvular infection and the offending organism is sensitive to antibiotics. Caution should be taken in concluding that a recurrence of IE represents a relapse rather than a reinfection. In one study that examined the agreement between time-based clinical criteria and molecular criteria to distinguish between relapse and recurrent infection in patients with recurrent IE due to the same species of bacteria, agreement occurred in only 10 (77 percent) of 13 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall embolization risk ranges from 13 to 44 percent in published reports. The risk of embolization tends to rapidly decline after the institution of effective antimicrobial therapy, and serious embolic events rarely occur several weeks after such therapy is begun. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications and outcome of infective endocarditis\", section on 'Embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no precise threshold for the number of embolic events that might mandate surgery. We and other authors generally advocate valve replacement surgery when a second episode of embolization occurs after the institution of appropriate antimicrobial therapy in patients with persistent vegetations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. Also, many patients who undergo surgery because of a large vegetation and recent embolic event have other indications for surgery, such as poorly controlled infection or infection with resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/22\">",
"     22",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence or opinion was in favor of the usefulness of surgery in the setting of recurrent emboli and persistent vegetations despite appropriate antibiotic therapy (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that embolism is more frequent than clinically appreciated if imaging tests such as CT scanning are used to screen for subsequent embolization. Many patients have multiple clinically \"silent\" emboli. Therefore, we recommend screening of all patients with large (&gt;10 mm) or mobile vegetations prior to surgery. The potential role of surgery to prevent embolization in patients with large vegetations is discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Vegetation size'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Surgical risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to surgical intervention in the setting of recent embolic stroke is uncertain. It has been widely assumed that cardiopulmonary bypass and its attendant need for anticoagulation increases the risk of extending a cerebral infarct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    converting a nonhemorrhagic infarct into a hemorrhagic lesion.",
"   </p>",
"   <p>",
"    A range of clinical experience regarding surgery in the setting of embolic stroke has been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 198 with IE complicated by ischemic stroke syndromes (30 percent of whom underwent surgery within 7 days after stroke and 70 percent of whom underwent surgery &gt;7 days after stroke), one-year mortality did not differ between the groups (27 versus 19 percent, p = 0.328). Neurologic outcomes were not reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 60 patients from a single medical center with left-sided endocarditis and underwent neurologic examinations and magnetic resonance imaging of the brain (regardless of neurological symptoms), no neurologic deterioration was observed among patients who were established to have a symptomatic cerebrovascular complication preoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review including 214 patients who underwent cardiac surgery (including 65 of patients with embolic stroke) demonstrated no difference in perioperative mortality between patients with embolic stroke and those without embolic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/25\">",
"       25",
"      </a>",
"      ]. However, mortality was increased among the 18 patients with stroke complicated by meningitis, cerebral abscess, or hemorrhage (39 versus 9 percent with uncomplicated stroke).",
"     </li>",
"     <li>",
"      In a retrospective study of 111 patients who underwent cardiac surgery in the setting of IE and cerebral infarction, exacerbation of cerebral injury (including death related to cerebral injury) was observed in 44, 17, 10, and 2 percent of patients in the first, second, third, and fourth weeks following surgery, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that the outcome may be best if surgery is performed at least two weeks after cerebral infarction and perhaps as long as four weeks after cerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. However, valve replacement surgery has been undertaken earlier than two weeks in selected patients with compelling cardiac indications (eg, moderate to severe HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/25-28,30,31\">",
"     25-28,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, some experts advocate proceeding with surgery if a large (eg, &gt;2 cm) mobile vegetation is present and the embolic stroke is small (less than approximately 2 cm) with no significant associated hemorrhage or edema. In such cases surgical delay can increase the risk of recurrent emboli and the risk of anticoagulation during cardiopulmonary bypass may be small [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/32\">",
"     32",
"    </a>",
"    ]. Management in such cases should be individualized depending upon patient condition, TEE findings, and the organism involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vegetation size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are conflicting, larger vegetation size is generally a risk factor for embolization. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link&amp;anchor=H17#H17\">",
"     \"Role of echocardiography in infective endocarditis\", section on 'Echocardiographic estimation of outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Timing of surgery in the presence of large vegetations was examined by a randomized trial in patients with native left-sided IE, severe valve regurgitation or stenosis, and vegetation diameter &gt;10 mm; the study compared outcomes of early surgery (37 patients) and conventional therapy (39 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All early surgery group patients underwent valve surgery within 48 hours while 30 of the 39 conventional treatment group patients underwent surgery during the initial hospitalization (27 patients) or during follow-up.",
"     </li>",
"     <li>",
"      Approximately half of patients undergoing early surgery had evidence of embolism on admission, but patients with major embolic stroke with a risk of hemorrhagic transformation were excluded. Other exclusion criteria included moderate to severe heart failure, IE complicated by heart block or abscess, destructive penetrating lesions requiring urgent surgery, and fungal endocarditis.",
"     </li>",
"     <li>",
"      The primary endpoint was a composite of in-hospital death and embolic events within six weeks. The primary endpoint was significantly less frequent in the early surgery group compared with the conventional treatment group (3 percent [1 patient] versus 23 percent [9 patients]). Similarly, the secondary composite end point at six months of death from any cause, embolic events, or recurrence of infective endocarditis was significantly less frequent in the early surgery group (3 versus 28 percent). The improved outcomes with early surgery were driven by lower rates of embolic events in this group, and in-hospital mortality rates were similarly low in both treatment groups.",
"     </li>",
"     <li>",
"      Study limitations included the limited number of endpoint events, the fact that the mean age of the two study groups was approximately 46 years, the small proportion of patients with infection with S. aureus (11 percent), the high proportion (22 percent) of patients with negative cultures, and the fact that 71 of 76 patients were enrolled from a single medical center. The scope of the study was limited to patients with large vegetations with severe native valve disease (who are likely to require valve surgery). Also, 26 of the 134 patients who received a diagnosis of IE during the study period underwent urgent surgery before assessment for eligibility for this randomized trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are limited regarding utility of surgery in patients with mobile vegetations greater than 10 mm, with or without embolic events (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9\">",
"     9",
"    </a>",
"    ]. Progressive increase in the size of vegetation(s) during treatment has been associated with a less favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgery is not routinely indicated for an increase in vegetation size in a patient who is otherwise responding well to medical therapy but may be warranted for patients with unsatisfactory clinical course.",
"   </p>",
"   <p>",
"    Given the results of the above small trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/33\">",
"     33",
"    </a>",
"    ], we suggest early surgery as a means of reducing the risk of embolism in patients with vegetations &gt;10 mm who have severe valve regurgitation or stenosis and no coexisting major embolic stroke. It is our opinion that vegetation size greater than 10 mm by itself, without other complicating features as above, is not sufficient to require surgery, but it may be an important ancillary finding in patients with IE who have borderline or equivocal traditional indications for valvular surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RELATIVE INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Extravalvular extension of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection extending beyond the valve leaflets occurs in 10 to 20 percent of patients with native valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/35\">",
"     35",
"    </a>",
"    ]. Persistent fever, the appearance of electrocardiographic conduction defects, and pericarditis are clinical clues that suggest perivalvular extension.",
"   </p>",
"   <p>",
"    All patients with IE should undergo TTE, but TEE is more useful when complications are suspected. TEE is much more sensitive and specific for the identification of perivalvular problems, and is invaluable for the identification and definition of complications that may otherwise go unrecognized even at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study of 44 patients with IE complicated by abscess formation, TEE detected 40 of 46 areas of abscess compared with only 13 of 46 with TTE (87 versus 28 percent sensitivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/37\">",
"     37",
"    </a>",
"    ]. Preoperative cardiac catheterization is not recommended except in selected patients who may be at high risk for the presence of coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When infection extends from the valvular structure into extravalvular tissues, the prospect of cure with medical therapy diminishes substantially. As an example, in one study of 233 patients with a perivalvular abscess, 20 patients were treated medically; the mortality was 40 percent and after six months an additional 40 percent had at least one complication including recurrent sepsis, HF, or renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, presence of this complication is a strong indication for surgical intervention. In one series of patients with IE complicated by annular abscess formation, for example, the survival of patients with medical therapy alone was less than 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The operative mortality for patients with IE and annular abscesses has ranged from 19 to 43 percent in various series and in one series of 233 patients, the survival at 27 months was 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/38\">",
"     38",
"    </a>",
"    ]. Independent risk factors for operative and long-term mortality were age, staphylococcal infection, and fistulization of the abscess; renal failure was also a risk factor for operative mortality. Nevertheless, most authorities advise surgical intervention whenever possible in patients with extravalvular extension of the infective process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high morbidity, recurrence, and mortality for patients with annular abscesses with either medical or surgical therapy provide a rationale for earlier referral of patients with difficult to treat organisms for cardiac surgery in an effort to avoid abscess formation.",
"   </p>",
"   <p>",
"    In our experience, fistula and aneurysm formation due to extravalvular extension of infection are often fatal and typically require complex repair procedures by a surgeon skilled in such unusual operations. However, small valve ring abscesses may occasionally be detected by TEE in patients with IE who are responding well to antimicrobial therapy. In some cases, medical therapy alone can achieve cure; in others, the annular abscess may enlarge and result in heart block or fistula formation that ultimately will require surgical replacement of the affected valve. On the basis of this information, we recommend continuing medical therapy in patients with small (2 to 3 mm in maximum diameter) ring abscesses who are doing well. Patients with larger perivalvular abscesses, those with enlarging small abscesses, or those with clinical deterioration require surgery.",
"   </p>",
"   <p>",
"    When medical therapy is chosen over surgery in such patients, we recommend continued vigilance for further extension, such as serial electrocardiograms and repeat transesophageal echocardiography at periodic intervals during therapy (eg, weekly or every 10 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Difficult-to-treat pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain pathogens, such as Pseudomonas aeruginosa, Brucella, fungi, and gram-positive cocci that are resistant to beta-lactam antibiotics or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , are extremely difficult to cure with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/29\">",
"     29",
"    </a>",
"    ]. Although a few patients with fungal endocarditis have been cured with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], most patients with Candida endocarditis and virtually all patients with other forms of fungal endocarditis require surgery to control their infection. Morbidity and mortality in patients infected with these pathogens who are treated surgically is substantially increased by associated morbidities (such as end stage renal disease and hemodialysis or immunosuppressed states from chemotherapy or HIV infection that are frequently associated with these entities).",
"   </p>",
"   <p>",
"    Even with surgery, there is an appreciable mortality rate in patients with fungal endocarditis. In a literature review of 270 such patients, mortality was related to both the type of therapy and the causative organism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the 103 patients with Candida endocarditis, the overall mortality rate was 50 percent. The mortality rate was significantly lower in patients treated with antifungal agents and surgery compared with those treated with antifungal agents alone (42 versus 59 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    .) In contrast, 14 of 16 patients (87 percent) with Aspergillus endocarditis died despite combined therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Persistent fever on appropriate antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with culture-proven IE have persistent fever that lasts for more than one week after appropriate antimicrobial therapy has been instituted. Such patients need a meticulous clinical evaluation for signs or symptoms suggestive of metastatic infections (eg, to the brain, spine, or visceral organs), drug fever, or the presence of a confounding secondary (usually nosocomial) infection. If fever persists after a thorough evaluation has eliminated these alternate causes of fever, and if other signs of uncontrolled infection (such as recurrent embolization, enlarging vegetations or other signs of extravalvular, intracardiac extension of infection) are present, cardiac surgery may be necessary.",
"   </p>",
"   <p>",
"    In our experience, fever is rarely the only manifestation of uncontrolled intracardiac infection in patients with IE. Most such patients have one or more other manifestations of active uncontrolled cardiac infection such as signs of extravalvular extension, HF, or recurrent embolic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there have been concerns about a high surgical mortality and the risk of early recurrent endocarditis, the outcome of surgery in such patients has been surprisingly good, particularly when surgical treatment includes complete removal of all infected and necrotic tissue. The Gram's stain of resected valves or cardiac tissue is often positive when surgery is performed before the completion of a standard course of antimicrobial therapy. However, in most such cases, simultaneously obtained blood cultures are negative, suggesting that dead microorganisms may persist in vegetations despite microbiologic cure.",
"   </p>",
"   <p>",
"    These issues were addressed in a retrospective review of 480 patients who underwent 506 valve replacements [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/45\">",
"     45",
"    </a>",
"    ]. In patients whose valves were removed prior to the completion of a standard course of antibiotic therapy, Gram's stain and culture of valve material were positive in 231 of 285 (81 percent) and 125 of 306 (41 percent) of cases, respectively. In contrast, cultures of heart tissue were positive in only 9 of 92 patients who underwent surgery after completing more than 50 percent of their expected medical therapy and in 6 of 53 patients who completed their full course of medical therapy prior to cardiac surgery. Three of the patients with positive cultures at the completion of medical therapy had difficult-to-cure organisms (eg, Aspergillus, Brucella, enterococci), and one each had an intracardiac abscess or large vegetations. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Difficult-to-treat pathogens'",
"    </a>",
"    above.) However, these are not randomized trials and they involve highly selected populations. The typical goal of medical therapy prior to surgical intervention for other indications are negative blood cultures rather than full course of medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing for surgery in native valve endocarditis is uncertain. In some cases, surgical intervention is delayed due to concerns about placing a prosthetic valve into actively infected tissue. On the other hand, early surgical intervention may be curative and life saving if it is done as early as the first or second day of diagnosis in patients with acute valvular regurgitation and severe congestive heart failure. Although some studies show lower mortality rates with a longer duration of antibiotic therapy prior to surgery, these studies are affected by selection bias as patients who survive longer with medical therapy alone are at lower risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/26,46\">",
"     26,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies support the use of early surgery in patients with appropriate indications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/8,47-50\">",
"     8,47-50",
"    </a>",
"    ]. As an example, the outcome after surgery for active native valve endocarditis was evaluated among 138 patients who underwent valve replacement in the presence of culture or histologically proven active infection. Early mortality due to heart failure or multiorgan failure was 11.5 percent, and only 2 percent had early recurrent endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/47\">",
"     47",
"    </a>",
"    ]. Risk factors for early mortality were NYHA functional class IV or cardiogenic shock, advanced age, preoperative acute renal failure, and staphylococcal infection. There was no increased risk associated with the site of infection, number of valves involved, or presence prosthetic valve.",
"   </p>",
"   <p>",
"    The authors of a later review concluded that early surgery was warranted in patients with clear indications (eg, aortic regurgitation with heart failure, perivalvular extension or persistent infection, or high embolic risk), because the prognosis for such patients was poor with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the available evidence, we recommend that surgery NOT be delayed when any of the indications discussed above are present, regardless of the duration of preoperative antibiotic therapy (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 1",
"    </a>",
"    ). Evidence of benefit from surgery in patients with large vegetations with severe valve disease is discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Embolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;When surgery is performed in the setting of active infection, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended that valve repair is preferred to valve replacement. As mitral valve replacement is associated with a risk of infection of prosthetic materials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9,51,52\">",
"     9,51,52",
"    </a>",
"    ], mitral valve repair is preferable if it is technically possible. Aortic valve repair is also preferred to aortic valve replacement. However, such repairs are possible in a minority of cases such as when a leaflet perforation occurs without extensive leaflet destruction or annular involvement.",
"   </p>",
"   <p>",
"    Among patients with severe chronic mitral regurgitation (MR) not related to IE, mitral valve repair reduces operative mortality and improves long-term outcomes compared to mitral valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Valve repair versus valve replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are more limited on mitral valve repair for IE. It has been most often performed for partially treated or healed disease and less often for active IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/46,51,53\">",
"     46,51,53",
"    </a>",
"    ]. The outcome after mitral valve repair in active IE was evaluated in a series of 37 consecutive patients, 31 of whom received a prosthetic annuloplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/51\">",
"     51",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient died, while the most common causes of perioperative morbidity were a low output syndrome and transient complete AV block, which occurred in 13 and 8 patients, respectively.",
"     </li>",
"     <li>",
"      At 10 years, the survival rate was 80 percent, repeat mitral valve surgery was required in 9 percent, and all but one patient were New York Heart Association class I or II (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Valve repair may be particularly desirable in young intravenous drug users in whom compliance with anticoagulation required for mechanical prosthetic heart valves is often poor and use of a bioprosthetic heart valve is associated with a high rate of structural deterioration over the long term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Outcomes with valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of patients undergoing prosthetic valve replacement for native valve endocarditis is good, with a low risk for reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. One study, for example, evaluated 50 patients who underwent valve replacement after six weeks of antibiotic therapy; the 30-day mortality for native and prosthetic valve replacement was 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/54\">",
"     54",
"    </a>",
"    ]. The survival at one, five, and seven years for native valve endocarditis was 80, 76, and 76 percent, and no patient required reoperation. The five-year survival was the same for aortic and mitral valve endocarditis (75 and 79 percent).",
"   </p>",
"   <p>",
"    Despite the generally favorable outcomes with surgery in patients with the indications discussed above, predictors of poor outcome have been identified. In a retrospective study of 383 patients with active IE, 69 percent of whom had native valve endocarditis, preoperative shock, perivalvular abscess, left ventricular ejection fraction &lt;40 percent, and infection with Staphylococcus aureus were predictors of operative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/56\">",
"     56",
"    </a>",
"    ]. Age and recurrent infection also adversely affected long-term survival.",
"   </p>",
"   <p>",
"    Patient-related social issues, such as intravenous drug abuse, especially if not fully addressed and corrected, have also been associated with worse long term outcomes. In a retrospective review of 197 adults undergoing surgery for endocarditis, survival was significantly lower among the 64 patients with a history of intravenous drug use than among those without drug use at one year (78 versus 83 percent) and 10 years (41 versus 52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/32\">",
"     32",
"    </a>",
"    ]. Multivariate Cox regression analysis identified a history of intravenous drug use as an independent risk factor for diminished survival.",
"   </p>",
"   <p>",
"    Management of patients with prosthetic valves and prosthetic valve complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY FOLLOWING SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following valve replacement or surgical removal of vegetations with valve repair for active bacterial endocarditis, antibiotics should be continued for at least the planned duration of therapy (four to six weeks) with longer therapy if cultures of the surgically-removed tissue are positive.",
"   </p>",
"   <p>",
"    The 2004 European Society of Cardiology (ESC) guidelines on infective endocarditis recommend another full course of antimicrobial treatment if the valve culture obtained at surgery is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/10\">",
"     10",
"    </a>",
"    ]. If the culture is negative, the ESC recommends that the full treatment course be completed (counting the duration of preoperative antibiotics), but stipulate that treatment should be continued for at least 7 to 15 days postoperatively. The rate of relapse after surgery following such a regimen is very low (3 of 358 patients) in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration for surgery in patients with native valve endocarditis must involve a decision analysis that balances the risks of medical treatment with those of surgical intervention, including operative mortality and morbidity, recurrent embolization, co-morbidities, and the long-term complications of valvular prostheses and anticoagulation. Surgery should not be delayed to complete antimicrobial therapy in patients with progressive HF or evidence of other complications. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our recommendations are largely consistent with the 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association guidelines on the management of valvular heart disease, which include recommendations for surgery in patients with native valve endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/49/22297/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We recommend surgery for patients with native valve endocarditis who have valve dysfunction leading to heart failure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend surgery for patients with native valve endocarditis who have infection with difficult to treat pathogens (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend surgery for asymptomatic individuals with valve destruction resulting in severe regurgitation with hemodynamic evidence of elevated left ventricular end-diastolic or left atrial pressures (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend surgery for patients with native valve endocarditis who have persistent infection, including perivalvular abscess (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest surgery for patients with native valve endocarditis who have embolic events while on an appropriate antibiotic regimen OR associated with a large vegetation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Vegetation size greater than 10 mm by itself is not sufficient to require surgery, unless other complicating features are present. We suggest early surgery for patients with native valve endocarditis who have severe regurgitation or stenosis and vegetation &gt;10 mm with no coexisting major embolic stroke (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Vegetation size'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102938356\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, inc. would like to acknowledge Dr. Edgar Schick, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/1\">",
"      KAY JH, BERNSTEIN S, FEINSTEIN D, BIDDLE M. Surgical cure of Candida albicans endocarditis with open-heart surgery. N Engl J Med 1961; 264:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/2\">",
"      WALLACE AG, YOUNG WG Jr, OSTERHOUT S. TREATMENT OF ACUTE BACTERIAL ENDOCARDITIS BY VALVE EXCISION AND REPLACEMENT. Circulation 1965; 31:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/3\">",
"      Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA 2003; 290:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/4\">",
"      Durack DT. Evaluating and optimizing outcomes of surgery for endocarditis. JAMA 2003; 290:3250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/5\">",
"      Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis 2007; 44:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/6\">",
"      Cabell CH, Abrutyn E, Fowler VG Jr, et al. Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. Am Heart J 2005; 150:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/7\">",
"      Tleyjeh IM, Ghomrawi HM, Steckelberg JM, et al. The impact of valve surgery on 6-month mortality in left-sided infective endocarditis. Circulation 2007; 115:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/8\">",
"      Lalani T, Cabell CH, Benjamin DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 2010; 121:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/9\">",
"      American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/10\">",
"      Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/11\">",
"      Alsip SG, Blackstone EH, Kirklin JW, Cobbs CG. Indications for cardiac surgery in patients with active infective endocarditis. Am J Med 1985; 78:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/12\">",
"      Mullany CJ, McIsaacs AI, Rowe MH, Hale GS. The surgical treatment of infective endocarditis. World J Surg 1989; 13:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/13\">",
"      al Jubair K, al Fagih MR, Ashmeg A, et al. Cardiac operations during active endocarditis. J Thorac Cardiovasc Surg 1992; 104:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/14\">",
"      Larbalestier RI, Kinchla NM, Aranki SF, et al. Acute bacterial endocarditis. Optimizing surgical results. Circulation 1992; 86:II68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/15\">",
"      Blaustein AS, Lee JR. Indications for and timing of surgical intervention in infective endocarditis. Cardiol Clin 1996; 14:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/16\">",
"      Mills J, Utley J, Abbott J. Heart failure in infective endocarditis: predisposing factors, course, and treatment. Chest 1974; 66:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/17\">",
"      Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 2011; 306:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/18\">",
"      Pelletier LL Jr, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-72. Medicine (Baltimore) 1977; 56:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/19\">",
"      Karalis DG, Blumberg EA, Vilaro JF, et al. Prognostic significance of valvular regurgitation in patients with infective endocarditis. Am J Med 1991; 90:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/20\">",
"      Chu VH, Sexton DJ, Cabell CH, et al. Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis 2005; 41:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/21\">",
"      Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/22\">",
"      Tornos P, Iung B, Permanyer-Miralda G, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005; 91:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/23\">",
"      Barsic B, Dickerman S, Krajinovic V, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 2013; 56:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/24\">",
"      Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 2008; 47:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/25\">",
"      Ruttmann E, Willeit J, Ulmer H, et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke 2006; 37:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/26\">",
"      Eishi K, Kawazoe K, Kuriyama Y, et al. Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg 1995; 110:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/27\">",
"      Gillinov AM, Shah RV, Curtis WE, et al. Valve replacement in patients with endocarditis and acute neurologic deficit. Ann Thorac Surg 1996; 61:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/28\">",
"      Matsushita K, Kuriyama Y, Sawada T, et al. Hemorrhagic and ischemic cerebrovascular complications of active infective endocarditis of native valve. Eur Neurol 1993; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/29\">",
"      Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation 2010; 121:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/30\">",
"      John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/31\">",
"      Maruyama M, Kuriyama Y, Sawada T, et al. Brain damage after open heart surgery in patients with acute cardioembolic stroke. Stroke 1989; 20:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/32\">",
"      Rabkin DG, Mokadam NA, Miller DW, et al. Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann Thorac Surg 2012; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/33\">",
"      Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 2012; 366:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/34\">",
"      Rohmann S, Erbel R, Darius H, et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr 1991; 4:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/35\">",
"      Carpenter JL. Perivalvular extension of infection in patients with infectious endocarditis. Rev Infect Dis 1991; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/36\">",
"      Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echocardiographic recognition of subaortic complications in aortic valve endocarditis. Clinical and surgical implications. Circulation 1992; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/37\">",
"      Daniel WG, M&uuml;gge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/38\">",
"      Choussat R, Thomas D, Isnard R, et al. Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. Eur Heart J 1999; 20:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/39\">",
"      Rohmann S, Seifert T, Erbel R, et al. Identification of abscess formation in native-valve infective endocarditis using transesophageal echocardiography: implications for surgical treatment. Thorac Cardiovasc Surg 1991; 39:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/40\">",
"      Moon MR, Stinson EB, Miller DC. Surgical treatment of endocarditis. Prog Cardiovasc Dis 1997; 40:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/41\">",
"      Kanawaty DS, Stalker MJ, Munt PW. Nonsurgical treatment of Histoplasma endocarditis involving a bioprosthetic valve. Chest 1991; 99:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/42\">",
"      Faix RG, Feick HJ, Frommelt P, Snider AR. Successful medical treatment of Candida parapsilosis endocarditis in a premature infant. Am J Perinatol 1990; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/43\">",
"      Mayrer AR, Brown A, Weintraub RA, et al. Successful medical therapy for endocarditis due to Candida parapsilosis. A clinical and epidemiologic study. Chest 1978; 73:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/44\">",
"      Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/45\">",
"      Morris AJ, Drinkovic D, Pottumarthy S, et al. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. Clin Infect Dis 2003; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/46\">",
"      Lee EM, Shapiro LM, Wells FC. Conservative operation for infective endocarditis of the mitral valve. Ann Thorac Surg 1998; 65:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/47\">",
"      Bauernschmitt R, Jakob HG, Vahl CF, et al. Operation for infective endocarditis: results after implantation of mechanical valves. Ann Thorac Surg 1998; 65:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/48\">",
"      Middlemost S, Wisenbaugh T, Meyerowitz C, et al. A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol 1991; 18:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/49\">",
"      Habib G, Avierinos JF, Thuny F. Aortic valve endocarditis: is there an optimal surgical timing? Curr Opin Cardiol 2007; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/50\">",
"      Foghsgaard S, Bruun N, Kjaergard H. Outcome of aortic homograft implantation in 24 cases of severe infective endocarditis. Scand J Infect Dis 2008; 40:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/51\">",
"      Zegdi R, Debi&egrave;che M, Latr&eacute;mouille C, et al. Long-term results of mitral valve repair in active endocarditis. Circulation 2005; 111:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/52\">",
"      Iung B, Rousseau-Paziaud J, Cormier B, et al. Contemporary results of mitral valve repair for infective endocarditis. J Am Coll Cardiol 2004; 43:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/53\">",
"      Dreyfus G, Serraf A, Jebara VA, et al. Valve repair in acute endocarditis. Ann Thorac Surg 1990; 49:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/54\">",
"      Delay D, Pellerin M, Carrier M, et al. Immediate and long-term results of valve replacement for native and prosthetic valve endocarditis. Ann Thorac Surg 2000; 70:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/55\">",
"      Meszaros K, Nujic S, Sodeck GH, et al. Long-term results after operations for active infective endocarditis in native and prosthetic valves. Ann Thorac Surg 2012; 94:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/56\">",
"      David TE, Gavra G, Feindel CM, et al. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg 2007; 133:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/49/22297/abstract/57\">",
"      Morris AJ, Drinkovi D, Pottumarthy S, et al. Bacteriological outcome after valve surgery for active infective endocarditis: implications for duration of treatment after surgery. Clin Infect Dis 2005; 41:187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2148 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22297=[""].join("\n");
var outline_f21_49_22297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Asymptomatic severe valvular regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complicated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Surgical risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vegetation size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RELATIVE INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Extravalvular extension of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Difficult-to-treat pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Persistent fever on appropriate antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Outcomes with valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTIBIOTIC THERAPY FOLLOWING SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102938356\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/50/38699\" title=\"table 1\">",
"      Surgery native valve IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/6/11373\" title=\"table 2\">",
"      ESC indications for surgery for endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/19/22844\" title=\"table 3\">",
"      Severity of AR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/46/35564\" title=\"table 4\">",
"      Severity of MR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 5\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_49_22298="Pemphigus vulgaris biopsy";
var content_f21_49_22298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60749%7EPC%2F66267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60749%7EPC%2F66267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic specimen of a bullous lesion in a patient with pemphigus vulgaris demonstrates the characteristic loss of cohesion between epidermal cells (acantholysis) with an intact basement membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This hematoxylin and eosin stain of a skin&nbsp;tissue biopsy specimen from the edge of an established lesion of bullous pemphigoid demonstrates a subepidermal blister with an edematous papillary dermis as its base. The roof of the blister consists of the intact epidermis, including the stratum basalis. Eosinophil-rich inflammatory cells, fibrin, and tissue fluid fill the blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, E, Farber, JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22298=[""].join("\n");
var outline_f21_49_22298=null;
var title_f21_49_22299="Considerations for the diagnosis of pediatric RLS";
var content_f21_49_22299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important considerations for the diagnosis of pediatric restless legs syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          The child must describe the RLS symptoms in his/her own words",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          The diagnostician should be aware of the typical words children and adolescents use to describe RLS",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Language and cognitive development determine the applicability of the RLS diagnostic criteria, rather than age",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          As in adults, a significant impact on sleep, mood, cognition, and function is found. However, impairment is manifest more often in behavioral and educational domains.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Periodic limb movement disorder (PLMD) may precede the diagnosis of RLS in some cases",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RLS: restless legs syndrome; PLMD: periodic limb movement disorder.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the International Restless Legs Syndrome Study Group (",
"     <a href=\"file://www.irlssg.org\" target=\"_blank\">",
"      www.irlssg.org",
"     </a>",
"     ). Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22299=[""].join("\n");
var outline_f21_49_22299=null;
var title_f21_49_22300="Encephalitis travel history";
var content_f21_49_22300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Travel history and possible etiologic agent(s) of viral encephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Travel",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible infectious agent(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Africa",
"       </td>",
"       <td>",
"        Rabies virus, West Nile virus,",
"        <em>",
"         Plasmodium falciparum",
"        </em>",
"        ,",
"        <em>",
"         Trypanosoma brucei gambiense",
"        </em>",
"        ,",
"        <em>",
"         T. brucei rhodesiense",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Australia",
"       </td>",
"       <td>",
"        Murray Valley encephalitis virus, Japanese encephalitis virus, Hendra virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central America",
"       </td>",
"       <td>",
"        Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St. Louis encephalitis virus,",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"        ,",
"        <em>",
"         P. falciparum",
"        </em>",
"        ,",
"        <em>",
"         Taenia solium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Europe",
"       </td>",
"       <td>",
"        West Nile virus, tick-borne encephalitis virus,",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"        ,",
"        <em>",
"         Anaplasma phagocytophilum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        India, Nepal",
"       </td>",
"       <td>",
"        Rabies virus, Japanese encephalitis virus,",
"        <em>",
"         P. falciparum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Middle East",
"       </td>",
"       <td>",
"        West Nile virus,",
"        <em>",
"         P. falciparum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Russia",
"       </td>",
"       <td>",
"        Tick-borne encephalitis virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South America",
"       </td>",
"       <td>",
"        Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St. Louis encephalitis virus,",
"        <em>",
"         R. rickettsii",
"        </em>",
"        ,",
"        <em>",
"         Bartonella bacilliformis",
"        </em>",
"        (Andes mountain),",
"        <em>",
"         P. falciparum",
"        </em>",
"        ,",
"        <em>",
"         Taenia solium",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southeast Asia, China, Pacific Rim",
"       </td>",
"       <td>",
"        Japanese encephalitis virus, tickborne encephalitis virus, Nipah virus,",
"        <em>",
"         P. falciparum",
"        </em>",
"        ,",
"        <em>",
"         Gnathostoma",
"        </em>",
"        species,",
"        <em>",
"         Taenia solium",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. Copyright &copy; 2008 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22300=[""].join("\n");
var outline_f21_49_22300=null;
var title_f21_49_22301="ALA dehydratase porphyria";
var content_f21_49_22301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Enzyme defect in ALA dehydratase porphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 192px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of the enzymatic defect in 5-aminolevulinic acid (ALA) dehydratase porphyria (ADP). This disorder is characterized by a defect in the enzyme ALA dehydratase (ALAD), leading to the accumulation and excretion of ALA. The reduced production of heme also contributes via loss of heme-mediated repression of ALA synthase (ALAS), the enzyme that promotes the formation of ALA from glycine and succinyl CoA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22301=[""].join("\n");
var outline_f21_49_22301=null;
var title_f21_49_22302="HDL-C and LDL-C levels and CHD risk";
var content_f21_49_22302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Risk of coronary heart disease is associated with HDL- and LDL-cholesterol levels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 323px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low levels of high density lipoprotein cholesterol (HDL-C) are associated with an increased risk for coronary heart disease (CHD), especially when low density lipoprotein cholesterol (LDL-C) levels are also elevated; the risk is lower as HDL-C increases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harper CR, Jacobson TA. Arch Intern Med 1999; 159:1049.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22302=[""].join("\n");
var outline_f21_49_22302=null;
var title_f21_49_22303="PUPPP hives and plaques";
var content_f21_49_22303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PUPPP hives and plaques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECAYgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDudVYRQJHGW3vhRjNMiVIgET0wOKhZ/PvZJj9yPhfc96ZeXsdvG7s6qiAkk9AK72+oyxcXKQKdzDOOSeBXmHizxAdUZrW0Yi2HDyD+P2Ht703xJ4hk1NpILditoeGPQyf/AFq5x5AAcYxjsK4K+I5vdidlCh9qRE21VwoAA9KiJ44/Ogtk9Rn69KTtxxXEdqEbjOf5U3I9MinkA56UYxk/y70FIZ1z6UvHoKfxk560hxnj8fagY09femMeTT+3SmsOfxoGhmeBig+3Sn446ZpCB6cUDI/4aO3r/WnHp/hSEZUYGaBjf0pAenFPAGfTtSKPTNAWGe/FKAMdKdt4pccAU7jsMwM9KMe3NSAe3pQQAOMUXHYiZQUI5GfTrS7cLwOnSpAp6Y/Ol28ccjPelcLK5EQPypCgPp+VTED0/KkwOe/vRcdkQNGDkgYphjYdCassOaQjimpGbowfQr5cHse1J5jKOQcH2qZk+b1xTdvtzVXRHsmvhYize/PelEgpGQEfdqMx/wB1iKLIhupHzJfMz070nme9V3WQY6Go2dgfmBBqlAwniZR3RaL+lJuGBVXzCaQufWnyGEsVctGTsaQuPWqu85FG40+Uh4hlkuO/WjfVbdS7qOUn2zLO8YpC3Wq4Jo3Ucoe2ZZLCkJHtVfcaUscUcoe2J+PQUhwR0GfpUW6jcadifaIlGwj7opMLzxUZOaXNFhcy7D9qelFMzRRYnmPoie6SytiXcKANzFjjnua838Sa+2pyeVFuS0HO0n759T7egqv4q199WvJEgJFijfIpHL4/iP8AQVhq249c5rSvX5vdjsddCklrIlZyRweKhLEnAxSjOM0zvx2GMVyHahQePX6UAHr3o54Hb60v4e1IsCOPWmg5PHejt6DrSc4/woGhQ3PHNB9zQAcYA/ClINAAelIcZP8AWlI7Z5J60hHpSGhpPpikPbmlf7vtSYOc/nQUMPTg0YPoBTgOT396GUbeBQAgpMdMYNKB3FCqc0DG/TFOUEAZ4p4XjvnHNCjHrjvRcYgBHb8KTGRwTn0xUgTPQZHGc0/YGwOSfalcZEFHQnP0pendefbmpShA5HB6CkKEEDnn2pXAixj72OeR7UhAHTHXOKkIwmeg603b12njNMCP1GM00DPOCKl2nB6E00oQMD8fpTuMZ15zTT8w6d6lKnOMHNNKnbyPancRHtzz7UhAwe/41JtJx1puOM9adyWiIjGKQgHjHFSMmcnt601kz15+lNMzlC5A8KkdMVE0JHQ1b2+npTCuMcVakcc8NF9CmUYdqSrhWmNGD2qlI5pYdrYrflRUzQjtxTDEfWqujF05IYKWl2EGkINMmwUUlKelAgpaSloAKdTaWgBaKKKQG0i5xmnDrijsP60AdM4rBnrRVtgHqcUnJwcdqUcA9aQdeM+lSaoB6f1pME9TSjg8UtIoQjII60BRmlwO5pQOfQUDQgXjv9aGHanY4Ocikxjr07UDG44PQ5pCPrjOKeV4xg0bexB+tAxpH4U1R04BqVuR0x6UbcjkAUrjI+SPpTgp69Oehp6pnIBHHU04pjoB+NK4yALyaVRj1IqbyyxAAGcYNKqDALg568UrjIhGcDPAHpTlTavK/TNTony8EZHNOKHjau71z0ouBXCMTktu+tSoCfu4A7DNGAFOFyw69uaikdlHy5HsDzSKSuTkAY24BP500qSCCKmjiIi5JB4zxzSop3HB2jpg96VxbFYxYGQuKiZeOBz9OtXZISTu259MnrTHHbPQemKdwuU2QlSCfwpNh78dc4qyisRy36ZpGjG4kHj86dwK+z8R7UBWYHC9RgZq0Ixt9z6dKi4AwRzRcRAYxx69aYy8ED0q1s3c4HqDmmFAo/8ArVVwKzIcU0LnFWGU4JBphTIAzTuBAydMCm7O1Tsp703HHAP400xctyErmmleB1qfb82MCkKnHNVchwINvXigpmpSKTHHNO5i6SISlMKdeKsFaQrwRTUjGVArNGPSmMlWitIU4qlI55UCrtNGPzqwUphTiq5jGVNoixRTyuKTFMzEopcUUCNsY9OaM4x2o7/54o/wrBnspACOp6mk5PPtSgde9IBz+FSWkFKPU8CnAZOBn60qr/ez7UihFGDwAKXGDjPNLjnIHXtSgZz2H6UhpCBf7x4FKRkn2oYEA4U5+lOUZGWzmi5VhpU9c9PSl2kDnOT3qUrgZ4T1oONuVDfj3pXAiZcjvz+tKF5+YE4/SpkUDnPPrjgUHcwwh47nFK4xnlgHoR9OlL5TckED0qXjYcnLdM96EGHGSR7d6VxjfLyMbsY7DvTWJG0E4H86mbhjgEjjPqaU2xlfLJtU9BnOKVwXmCoW45I44H+NSLAM7d7bcDCgZOanjXyk/dPt9cjOTUgUYVnJBxnccjJpXEVTbKExEN4PIAGTmltLMyLvmwigcdyT6VowRELjAwe56j8KnSOPktGGYcYUZ/Si/QXO0UbiEKm2NFGe5bt/jTFt1XAA3FhyxGOfatLyiw+ZQDj06fWkjiMTkyOzluOB09qSFfQxhC5kYrKSnckf5zSXEWeeSBnknkitOZWAZpELFjkbun5VTlSVyMqM9hnrTuVe5W24bYCMEZx0pGUIF3MpA/h9anitHUfNHklsEk9PepY7bcSQq7c4JY9OtFx6FF4yXyoCnjKgd6Y6B2VUjyW4JOK0xGwJCZJA79Px5pgiXZksoJ4xjmhMVykYdmFwoAwSKhkVG3FSD/npV+VAPldS+DjPTHrUXknbuEe4ZxTuCKBiDEj5QaaY2C/TuK0zCzglkC46561C9uzOcYKds8Ci5RQZQqjC4/CowCVx2xWgY8n5sk+uOKiZCeAOOxxTTAo7eKaynPCmrjRHj5RmmMmBgg/hVJisVGQj649aawABA5q2V2jtzTGUdeR9RVJisVsDjp7U0rgGrOOcf0pjLmncTiQlSScY96aRxU5U8mmsnXjFO5Dpohx/OmlanK+n1ppXrx+lUmZSpEBXmmFeassue3FMK9eOapSOSpRK5XniipmXNFUmc7pNGmOlLz6c0oGfalxyMc1iz1EhAB39PSlA59vWnKpI4FKq84OTx2NSWhvA6cnrTl3EdsdSacFO7j72M05Bz6jFIoYqHcQadhhJ2GOnqasLG3fn0pGiDOp+ZjSGiPaRyRjPTHWn/cOG+Y/lTlHXc2GIyMc0p5XOTzwB1pDG4yozwOoBpfL2MCcZPSpAo4LkhUyMGlIzgHhew9qQEcy4cgsMe54pI0UAdTzgtUmAuGB3cfiPxponLN8kYOD0FIpK5KsauNkIXP8AeLfnTghJOzgDj5u9WbOCSSUyMPL9FxUoXaWaZMN2APvxUtibtoVokAU5aME8kd6litwzBssVx16DmrCDewCIvqSelTJlRiRgxz1A9T0x60tSblaNFB7bsjC4/lVyJNvRCR2xUqRcZMeB0JNSeUVUKi7RkngVSj1E3cjESMAH5bHINOjVY1IVSCeMj0qdEkPIXC+vrTkiYgklj6nHWr5RIieJSDlvnPHWoyhXgEbegI5Aq0yqw2qjYXj2prRkrksq45+92ocQM542ySSQG4ywqN4mzujchyc+oq95aybv4gP7wpoh6EJlvUnpUctirlEQyk7nw4HbpTUXGS6ADkgBs1pKpPBGdvYcVEIixJZFUnIz1NS4hcqiM+WDxznp3/OnyjK7lCKB3z0qykIVwIk4HGT3pTCSQNwGP4euaOVgZeHJBPIJ6txj8KdGhPBJz1O2r0iBSeC2e3SlRDGCcqueduKYzOWHywzFGA7se9RSwpIcruGeR+dabKZo1UKw5wNwI/Slkt2CbTs44yOuKWoJmN5b7MlPmzgAn9aaYpicSICTwCTW01srMDuIPt2qs8ALfM/Tpk8fhQO5kSQKvATkdecVCY22dACOlajoBIwlYswPC5HNVJoW3Hy8EnqF65qrjRnSRZJGRTWQDONxPHHpWlIpIBMZTtjqaqvA3JL8g/SmmUVihK5HIPFQtEQTxx6VoBRsPzAY9KjfBIDEY6cLimmIpsoz07dTTCvynORVtkBJ249qQwyFOBk+tNMVirt7YpuODxVl4jkkgtTHVtvIwAcVVxNFY9elIRz0FSkZPApCvtVXM3G5EVoqQr+NFO5i6aLmM805AARmkAPfpUnbAJpM0QoX5c5/OkGMYBJoXp8woXlh1J7UmUhyAZ4B69qkx6jj0z/nNLEqsCWOPQVIwYYwMhvWpKAOTleAO1MkVgOMnP604eWN3mAgAYwfWpEIPzBBsPAJ7Uh2sQAs0nzAH3qxs2gMnPoCaeNmcRb1z2IyTRl0Pyq5UZyT60rjBIv3/wA52kZ4xUojG3mRMZzgCmwuj/Kc7+eB29qkKtgKi4wOAP5n1NIjUhu4wYlVRvJOTtGKNNs3aQsiFiDjk9KuxRoUKsSmMnAXGTVm2RUiAQPjPpSuWpWVhGDrGynG5u6npSJCVXY6jeevORUy7wSWXbg8EntTym7kOQc9eKViBkUZTJyNnYAVIFWQZVfmx2qULIygLjHcnnNSLGQvJ4PPTrVqNxXFRHZQXkwOmBTyiMwxnPX2pV3ZyqDHGc1Oy7l+V1DY6e9aJCRHsaSYHzAka8Fcdanw2fkGR7nrT4YlVPmbdkdT3pCuUxv25/umqsNkTIpQ5OPbNRtEGJJxn37VMFQ4Vhx15HFIyJuACnaD+HSk0Mi8oqdxcBQPSooyZDhSu0H5jVwKjRgSMaiWONWzuIzzg0rBoRNHhm2fTJ6U3aAcu/y9ePSrFwj7cbyvbAHNNijAB3/N6DrSs72GkVsAKAnAJz7VFHE7sWO4p/KtMKhUOV6jHSkRFx9wp7460uW47lYIJeFZT6moxEwGMeYR3JyR+NXHUADap688Y4pqkZDRJweM9qbQkU0idpQSw64xnipGj4c7huqxtDKw9scHrSNDHnIdicc80rWKepnyW64XGeDnJ65qldoEwYsM/qBnmtl44mzgknpzzTRFuXnCAdl6mocbjWm5gW9q7sWY/L3GMVY+zMxyYxzxndwBWm9uEYbUzkdccVXCTICzyfKf4SKXK0EnfVGc0DqxDknj7vbFU5rfOWjRfm461tuFb7yn1ww6n2qnKsfIAYDnntU7EpsytmVVVUZHOQeKhkikRcyAY9RWiIYydiAntuUY5pxjKHAjbnuRTuXcy0QkkYGKdKpCEluO/bFX3iIX5XwQfTk1Xkh2D5izkdRjnFCYblGT8fXNRNGCfukZq66EZxHn0FRMjKck4+tWmOxTMXGADz78UwrgdcH0xV0rgZ2kg96jKddy4FO4rFMjLH9KKsumMdwe1FPmE0OTHqKVTySec0mQBknJpwzkHHNWzBCj0x1p2xhwBn2pF4PPSpkHzZOQOKktC8gL5eF4705w7LleFHY0hIjAALbu9SKgYrtyMDOM1IxiRFypbqO1WXB7IAMcHoKdEu5ix5T0Iz+dSxpJl9oDA+vv6UmwvcgiV3BIY5z0GBx/hU0alXY7S4PcHgVOqFAdmMc8jnNSIkmAUxzwd3b3pXC4kESqrMVUqTkDFKA0hK5xkdxz+HpUoIVFAB456daWGMheTl+hbPTnpQSM8mUyLnaRjrjn/PSrkaurBScgD2qI7zG20jeOAvtnrSWazSF3cLnPGByPahb6FJXRZIV32kE4GT6Ukiq2PmBAxgCpIxvBQkZFO8hlYOMAjpkU7XERorhAQxBPc84qRbYswk3FnPTPT8qlVZXAUr8o7k0KDlQVG7254+tWogidVYKqkKR6njNTpGiDLKoH160qRgsA56ds1ZC/LxjKj0/rVpAiEosmGxxnkdzTh3XywMdDipfkMgCnOe4HWnEf7GewyaZfLcgET7fk2kn9aYUcucIpb1B4q8q4QlBtI6cUzYyoQ+N5784oFylMQ7lAwCf4iT0qGSzQOCxJPOBnpV8Iqg/vMkf560xkC54c+ufSiyBKxT8oNjKkqOh6CpDH2jVgPekkjuJHCw4A64z2+tWPLk8sg4LdfQCkhuNip5RztySV6jtUhXgbmYHPSmuhEnDtkEHBp7QZbqSSMjn+VArDfnOB8oXqCfSkVE8rnntz/KrMcCuAJGyTzgCl2FgModg9RxRYdii0S7iyRknr1wKljjTnOOeeByPpVuONmO44CZ4xTdiR/NtAY+tFgKXlKX3BCFXPXjNNeM9myB2A5q6yHglSec4FIwLcmPaOu3vSsMoM4AKqhAHoKjnjd0XoAME+9X2jYkBV2qOpBxk1BPFsP+s3ZOMUmiWZzIGODg4HAboKhnITJkAODwuOnpV/yduSoz9eoNV5IgDsQFnPYGocdCSiYlUZYH2GOlRTjcCgJ9jWi1s+0fMM45GeKieBVXhQc9eMGocWikzIuUS0BdjuJ6c9BUsC+chZFwCM4z0/GtUwx7d23LEdxnJpNiKPlHJ647UuVmnMreZlSWoC5JAxxx0qvKjP91QMD7wGR+FbNxDlVVD8p561Qnt0TEYV8EcnNLYSfcz5YjuyrkrjotVJlL7ixwvpWq6CSUqkgUYxgf1qpJblmPXGcYHY00wM2RVJ4B9eaKveU2X3ge1FUpICkq5I796eOSAuenWolPPBqTOF6YrZnOhy4BAxmpl3dVA/HtUC8gA9xgU9CUH+1/KoZY/PZvxzxU1uqsWVX25HGR1qqzAgE7eKnsklaRJQwwex+lJ7FWui4sa/NjPy/eHQ5qRN+TtchScKM9OP880rFtpAC/KTwO9T4yVAXaW5POe1S2RckEbF1y3T+Ed6kUENxGSvbBqGKPDtsCnd1LHk1YQkoMEZzz/9akIciDGWJ6nk9DSl2D/LH8o5JJxTcSLITwccDnABqfG4DZgsD34xVAEMTkht+FI6Y5qRHCnaVAz0wvJpwL7MYAPtSudzBgRw2TgfnVWsguIAVkKhBk+1Wdp2rvbHcgUquoAVcFj70KFU5Jz25NUlYB8ZQ4UsFc9Mn+lTJtRiXxn6U3agIBx6kD0pyLEx24Bz+NUUiT5VIcDLEfeFTxwoykkkHqd38sUbfn+UKU6nmraMgUHO4/pVIoBGw2hEDKfelZjvG0Dd709GVVyrDcT2yaVWDLljyeS2MDigaGNC5QGQ4xwcDrSHGSEXOOM1I8m4KgVyhPJzT3Yr8ojULjIJ4zRYZTdWYr5SgMTgA0j85LZftwOBUpjEvKsCcdAePxp5DmLPC9l7YFFhMhUbuFCoevFNnUttIAwOfdvrSyDah3/M2eecZpzIqIpJI7gMeaYiu1uzqwIAI5OKYIdp2gnuN2eTVoAbMAkk9T3oEQUAABpOx680rDuRRQkFugHueanCtvJJwmOhH86lFvlcliAOSBinv5bIvI2/wg9aLDKvlAqx7nGAOgpNhZj5mzA4AP6mrkgBOST7c459qY8cflkyBfQCiwMqhRkyh8oM54qF8bcsSwY8EdTn0q7Kq+WN5HI3AYprqWUsAR2X1osGxWkBbASPr/e7VB5TIR8gJzxmrPltvUE7nJzlemKV4w7qshPsO5NFibGfLGSzHeO4HFVwnDqWGRySBg1oXCoCdxG4dPSopI1VMAZJPAx3pWEymqEEBIwY/U+lI+wRtgfpVtreTJBYYHUD/GoxtVzwDg4AFKwrFSMb/mK4PbPenNE20LhR3qxIgVzkhV6nFHkoQcHn1pco7lSa38xgzY2j068VVkTc3yqQoyB71pPCVXCEhvXNVpEZcjduI5yO9RKIGQ0SliVATjrVcwFeUOSR94nge9akkb53SDIPQf1qvcR7R8hAjzzk4yfSsWmirmYYyZcFgWPIz047UVYnD/KEwAepx3oouDOcHseKeO3SmKxHelC4IA710sxROrKBg4B6etNZucJnHrSA5UgdRyadGCUGMbSPxqWWhoBdwqgcj9avxowhVSVBPGR1PvUECcnbtGDjJq06NIMABsdCOlSxt9CS3kyWKrkqMdeKllfzTsCkEEZbt+FRQq8WFfbgZHBzU6QrI8m4FVXHfFSydL3J44SjtiXA6YFTbP3YEbbSf4iM/jUEUTmRSiqqDqM8f/rq5tdT0zwBmkhXEUsrbSCw5y3fFWEyWVVQspPOe1QK7CNyqAueg7VZWXYULKFzgHFXEdiZ5CV2KPmI/hHX8aihSUqu8ENnAyeP/r1bLYHC7k7Y4oYK4XcWX0xxVtagnZCCLAUBQRj73SlI2jJBPPAxzTjIQ5Gwk9SQKjjKNlY2O4d85zQCLYRDgsASRnJqeD5jnZjHGfWq8ETbcggOo+83OMVctll3HDDA5AxVFIlGYlw/QdABzUsJRiAMA46nimRsY1bzSN2D0HNWCkRUbR8w6Dt9BTRaFUKzHZGDxnd0xRtTJzgHsD2pUEuwkbVwc5P/ANagRNIysyBt3IHQD3pgxwOGO7B+uKRY26vllJz14NSLsckMM44BI4oljfaArEDHQ/ypiuRvEW+bPlpxnbUc0ZeVWBYYGBnoKmU/Ll2JYdMjGKTeF+8w6emMfSnYVyByVbqG9B6dqY8ZkVATg57c4p6hSWwuSx9ead5YLMzcnsM8UhjUj2NgMxB/HH4+tSgxxfIrDJ6nPIpsYck7sDBHb+VSBEUMAoxgj60AKpAj4yxPJB6mkaRIoWeVSmOCxGQOcDn609j+6UuAFHQmrChpIUAbBHcdxQMhCuQH2Yf2H86iY4A8xck8girBcK3lkZ3EYHJNLIsagBgzHPy+31oGVSDJjC7T3Df5/SomjIlUM2AOh9ffFXJVVk25IGM1H5eGGzH1PQChoCAOuWQHcMckdqhl2dVXc7HAPpVliEysaguRnjj/APVTWhXCO7hM/wB0Y/KgTK5i+ZlK7cdeehqHC9QGwBxgcmrcuzb+4iOw9Cef/wBdJHEfLJIA7gntT3JZUMG1uXYIBjHXJ+lR5LMSfujjIq6YjvPJBboM9KYIUCiMj7wPU9/p6UWJKTxRvCCy5XtT2h2pgHb2GKnaOPaEH3uoAFOZVOCdxz2HSlYZRK5O05Vf73eqrx+XlUBHcHHWtKZHUkgHJPrxVa4T93+9JLY6UmhGTKpAO5+vTb2qu0bbSozgDvWkI42kGVPTIqOWNNxTJwO/TNZOFx3M14wAAMkAfeFFXCiRMEQuNxI9aKj2dxcxwa9+9PHOBn86jxjp0p3Axkc1qyESKCOCefpTlbICkD3GKiHTnipVKkB+h61LKRJERuYMzL7+tW3kkQeWmFY457n3qomW5QAMD6danRi/38H0xUMbL0UuyNC7pu6ZbjFOdFaRx8u3g8nBx1P1qnAFYOUwTzktzU1pcBp9gXCgYAHOD3/CkxKPYuoGST5FXZtzk8EU+VphFmDhvXpUDEtJtYjHQlRUx80LtfBweHHUfWkJaE0LFiqgEOeWJ/xqKad/tYV0wueucYqzDgxbGIY45x/OmtHE8YVMFk9sZ70NaFxkr6l+CT92GYfMcn2qSJ2ZcMgBHHPP5VVLtEqbdrOQPpVhWJTK7Qw4IPrWidwaHk7eqkYPGOlQ29qY7kyox542t2/zmphkpg4DYxx0NMX7+wOWbjNN6gnY0EUNtbJyDnj9alRMOCZCFJ5INVY/nVdxJX1zUsUke/ZzuHTdV3BIvxSrGMMCfcVZj2NISzlfQelVIZkQYcFifQE5q0sgVlYwksTheRwP84po0RIGRpuVbIGR6Y9qI2jLMX6bsEg1GvEW2SUb243Yxn0FDYiVduXbGck5ApgSHZlsqAuOOMZ60hVgUK5AUk+n4k/561GZDw0kZz2Gc809DJJyeEIwB1J9/amSI3KjLA45wOuaH8tGHVs4HPWm5RX8sg4/vY/pT2UZXZgHIzk9aLhYGfYcmRVHaq/z7v3ZYZ4GKmdoxLtKl2HA2jOaaMsp3AKFwRk9PWi4JCRRsqsDJ8w/hJ6H1+tPVjGVwgdyMkev40gjCZ2nc5AOWPX/AAqTbISTgcce1IaHo7eaX8sdMlT2qxGXfKsuxTjIz1qF8FDtbexIByO/TH0oTlgqsWdTyfWmMlc+XudFAL9BT2feiGY7emcdfrioWPO13xnnBPWpx5Y+chT7scihDsV4YxJIWY4XsOv50skkjt0VcDAx3P8AnFPLMzkKpVW9qhdsHaVZiRjGMUxDdrgMzkDA4AGSaU7WQEgKuRgEZJPakado0KtwSMqAM80vmbAVkYkHoq9F9s9/8TQgY1txy6ISMcZqOTzC6szsMH7oHBpGmYupztU5PtgdBinGcEnYu7jb1zjvxTJZFNkHkEkYI74B7UEKq5Lcd8d/pUiFyvmnpnhc/eqJnRNuXBPsuAPagViQhEClhgD2zj6012G3IG044/z604S/NnAxgkDHJ5prNmLdgnJ4yuM470AREDYnBZu4I6f41TmRpB9wlQcAHnNXlDtGzcA9vSmzDChc4AwAx4H0osSzMmJyDGq8nJyeKYQsbhmAZsY4FW5YwWQBgMc8Ux1jEo5yzDH1pW6klX0G080VM42uoPT6fhRS5biPLAOeeaUDJABzTQMjHINKM881myUORcvg8GpQAp5POKiU7vXP8qcpy3ckjFSzRE6FiMAgH2FPj4PO7GDk1FGSH+Ycdj71LltpB2gnnmpGPjKmFsNt/rTrE+TIzg8E8DOBSEK6NwT0HPf/AD60igRzrkDjvjgCkykzQRllYea2HAJ+X/P1q1HJFIwV2bcnIP596ooyxyEhgCRjO79asQypCrjBAY5JAzgepqCGWpDGsbzL95TyQeQfT2qSxf7Tb7lxxxmosxPwEXaechhmokcR+YjMqkc7R8uR/jQVHVEkatHckyOMA8k+1PNyftJUcBjnk9aV4Uu1B3bRnk5zipTbKHAwepyw/nU2fQ2Ul1LyfvIc44J4bOTTxEQUIbjH3gMFjVNJJEIjMny44AHT1qwEfKnzWyeQa2TuZPcuxIQ33lGOCBU4kjC7MtubgkdqooN+dxBAOPqau25YJhRgD3q0CLY+dlADY7MO9WJXdWUD5s4yCcHFVEeYKpUKMYwM9KsqzFVcoGJHPNUWmSPKmfmwrHjntRBcjG0NuA/Dj60qPnnAwOP8/pUTvErFUKbh29TincdiZwRyWyvXk9KYGRiMSOu7gEsRTIjLtLSMqqDkDHalV0Lhcgn0b+lFwZNHyCCoCgEbvamKFxuB3DPfoT/WoSgzmX73fNChRHuQg4PB9BQInLsY/LVCOcZJHA602YbgN75AOAP/AK1MEhXDSfKMYBHamhEUlgMrnIOeMHtQIlSSNVDE7Sw5z60RTeYCu5i+ccHnFV3KSHuoX5v/ANVWGjTy1CnaB/d+lAyeILGr723N0Az9eKkjwkfzcEcDHf2qrvRCm4MWbof8aV5N2cAkH8AKYInkj3SxPlhjoalbYAWRi7r29Kph1yPMZ2BHCgUC4VcFVYg88L0oKJXZ3xgCPaM5Ldvp3pjNtjCZcucdeOPamNLmTG0gHoDxzThMC2MZwMH2oEPYvxu2F8Y256ewqvNIHzkEheC4/pTpNvmB8kkcnHSoPMeYsA5VTz+HpTESozzLJIAoQng+3T/69P8AlijIUqAR82f500MjMiKxbbzlRTFkyCAm0dwaZDGsSSXYfIDtU8/nTi6qyySKM8hVPYeuKhcO5KliAPfikACt8uSSOF/+vQBZaZZFBxtPOADj9aUSBEIY4HvwaqIyxMfMywwM8ck0LKp++cYycHk0DJt0igM+FPLfexx7VAx2AZOeON1RyOzNvHJHIIxxUW5TGXd23g4UehouSPzt3Scgn/OaVRukdl7dV7Z/pUcTDcMnL8DpTmZUzhi7HPJ9aVyWRyAFhufGO1FRNINu0nHOTkdeKKVyTzDpzQeo9KRcYwTxigHv1FSyESAkAnjBoD446E01W4JHpQoBGc1Joiyvzsu49envS7sMCpHTgVCjYBHehRlwe/qamxRbhGULbhzjPPvT0do8Arnj8KhjBxu4Vj6U+SXdng5I6/41LGixEytEVfoGOD1+tW4XgVfJ7/3fp71SinaMKSqsP1z6/lUqSlW3fKGPb1pNBYl3IDI0bsQPvAn/ADzTdQkLKjhgRn5DjtS4Ei5UYJ6qBzT2iiddhRN3X0IqS4vlZNa3Kn534ZjggDg++K0YZ1kiPlc45weuKo2tu3llZMcAnPcD3q5uAAOAMdyev40ldBKSew5ZCzcx4ZeDk1JJGIyJNx24+YD0qk2PtAJnKqP4c9/eraS7MgRkjpnPSmmiS9bGMksjErjgDkVZi35yZTknp7Vnb5I1BtwAOhA6Vbty7qWI8tsDrzWsZdB26mhGX8s7mxjjFPim8uRQzhsrgjODVG3by1XzsswPOOc1OSiOCVIOPTP41VykW5Wi+YKAv+9UkbRhOAoAxk9DVHCu+4oCx7GnMYo2VjH8uOuKYyyXAUncM5z+FRpPGr7MDcegHOP/AK1MKwyAOigbhg7gM/lVJoQtyCysCOhHGRSbaGrPRmsQWjDSN8pI5xyaZtidySzEg/dUYqKGNMB/4lzxnpS+cV3YhbPQnHWqbIHqYjhSwY54BPSk+0DcFA4HXAzzUAkXcTnaSMAml83qYdr56jsKVxk4kxI0bQk5GeSODTsyhSF2LF0PoKqsz71+fDA8gc4FKHUljIxB9B0p3EWJnlZsDD/hirCSygBG4I561RWYBwvm9BwMVKrbkzLIAeuR0NO47EhmnckybUC+nehXLPhd+AOretVjJ82IX+UHBYHPFI1ykch5JJ7AdqVxlxp8Nl3BfHBpyMzAbjwPf161S3RlhxhxyM00skRKkZc8kj+tCYmWJJXbKxY2kgHJoMoGc4B+7we3sKrGYp23j1xiopnMh6BVz27fjRcRY88qG8tQWYf5NEbyBQXwB1bvzVdZWTCrgE9yaCRuXEnB64NNMkmlnbI3t5gPAUdCPemo7OSVIAHQAc//AFqhR0diFXOO9MZpFYfvCEJ5Hr7GlzBYnDr/AAkM3qeTTIpBGSqoGAIJxyfzqLzNshCj5ieTTp5cBigVM8ZzwP8AGjmAlMyhQSpweeKgxuywJU5yAT0qubguowgcnPrwaZJLOpKRttHQk8UuYTRJM+0ookOc8/L2pfmCv5jAKTzt/lVdy5wSmVXJz3J/rUbSZUMW35PTNRzAWElGTn5uxPpRVJnCIRuBJJPHf6UVPtLE8tzhAeAOlAJzyBTQeelJn6/5xW7OZSJVPBGKVeuSOMUwf5FAY4H05qWjZMkHX07/AFp6cE44ao1x0PNOU9Dnjoagu5Jnfwxx71N8y4ORtPeoWYg/OOPWpEb5sBQVzSZSYAkSMFbgnkCtCFk3gNscjqRn+vFZ5wWwBlhyCaSP90/mKxPYik0Vua1uA0jumWbuM4GAKlWWQAuU2yZx2ODWVJO0T/u32hh0Axg1Yt5nmHllCwPAK9vepsPl6moJTgOwbf8Ad4HB9aA3ngAMAvIZTwarbpYAXBaRS3IIGRQDFIJHljbcnBOSCD+FQSTT7rdEKoZMkZJIJ/KryPMkahUOw8nLDIrJfy3JFozhlPOecD8elW/NljC9WYdR3oWg+hqBFkAZmO8HJX1NWEKsVIcjdxx6+hrJSdJiCSUbsHGD+B71Yt2wrl4js7+v/wBeqU9QNF5HgI2KCoz26VOsxWFG2ZzjIXjHvVTJkXEcuCB35xTvMdQqMGZfTvWt7Ai5KTJIckpxnAoMzhDnYWGcE5/zioFA5IfDkcjr+FNJkKchWHY9D+Ip3GmPeaCdTJGquBwVXB5pAsKYcxZ9ACagi2QZCw4BO7KjAJpXChy0bkgHlc9DSuU2i2JYsMXDLxyT2/Gpd6yx5gk+XjJ65FVwUKuGyQRyD0qC2wkbi2by8Hp2NMm5ZMoBO7A9xxTyuFBTbzntnFU5Z/m2SEmQ8DI6UvnR7kDqVIzg44ouFyz80S/u1DHPJJxThIyKfMXJbODVYFt3yFCuOBzSCR0fhyQByMUXHe5cVw3zYwRyDjj604ySsuHG4dCcYyKpSFAqgMVz6etEMoiGHkJzxz3ovYLloKQoCEL6KO3tRGpRt0mA3rnqarbkJOCfU5FDSNxtcBcbcYpXHcsNKr4VQdw7VCJFOEB5x0BOKrb9p2bTjGdxpUkcsQVA9D0J/ClzElwSEffbHtUJk85FydgVsD3/APrVE0h5PmHHp1qJvMmf97tVSchQP60+boInDKv3QWXk49aVSm0t93jqehqpJOdv3fxJps9ypQNIVJPp2qedAWorjzUyrbSvBprMxhTL/NgDPWs/7Thdsa/vMYz/AI1LGVUxjfuCAckj0qVPoBcDbFAdgWxk80yVRty7EkHI5qu86yybVU8feOOPwpy3KFMFRn/a+tPnQajmnYPgggYxxzzUO+OIk4PH54qNjub77Koz34PtVaXY0hQMcKASCefrU84tC69y5Rc5Ib+6OfwqAlXfcDnAHBOCaqz3GXRNynJH1AqO8ZHiwjnd1GOKlu4JEl7dILoAqC4OSfb2orCuUlldGJPpzxminbqacqM0EcdqX+IZxmoQ/NPB5FdrR5EZ3JARikzx/h3pAeKaOOO2Kg3jIkB5IxzTlJzjODUQwcf40DGevNI1UiyHDZRunrSq7KR6etRbuvQigHB/lUmqZZ3Kx7ZFJjjltpFRDAJ4607OQBnPNIZKwLYBBOOhFWraYwKfKbtzVNWCjKk4+tSbi/Rc46HPepaLvctm8kdQpI/KkSSOPc4kfzA36VSMxyccHpipVk3BRyRjke9Kw7F+C6QndjDPzkjv71NbP1DO7EZIGeQvoT9aoxzOUK+Xx1AOOaIJ4mYOh+cHB3ccd6hoVjWV4WyJQRhuFJwM+xqxaTIQVLCSM54JPH4VnxOAC2cqAAR1B96IzEziSzJVumV/qppbAbjJG6gxSOp7d6fDPKFG5QXxgt0BrKtHP/LQOjgHggAEdc5q1JdeUy5R8Hox71SlbUVnsXVuE84AkBiOR3qQyYJ2sw9cr/n9KqpMkjMXTYPUn9abI2GLxMcjsTmq5rIVy0ZVz+6kAbpg81GkjkgOQxBPfH5VUebdkSAI2Mg/5+tVA7qT58e4BsbkPPFTzDNV3dWLiQgkYKkdKXzcxnEig8kNWek424+cIM4Ujmobe4RnkV1Tytxxx0x9aXMNGn5j+Xg4DkdW706OV9oL4LE/w9M1nSmR3ZSqsuMjB6/SnRXMROxHKHnv0NCkMviWTe38IOPz9xS7nEirvVlByyg1UL/Kdzq47kcGnbkw2yQcdO/NPmEXRNtceYnTIyBnNCzs0IMiH1I64I96pW5mClpGXrwMcH/CnSTtnCoVbHTqCafP3GTyXCEnIIJ/hPemh0OURTuPPGeRUSzDkGIhh355/Oq0jy79zFUU8c8j/wCtUuQFpfNdmy5GCQvc0JN5O4SOMe/X86gLnBywBOTkHvVVvMSRX3eYH9euKm4r3L7TGNyY8NnjIOePSopZJTGADtOeD1zVd/KjhYpsUtxk/wCNVbklQFRlx3+csBQmwSuX4Z2CESYVvY8ULJEd7DAPQc5J96oyPDFGGOwnqR0NOF1tX5IQigcEjAoQmXIZUkRtyEnkelMimcySIqlNo69hmqjTPKoCSKM+g5FNguDFFIXJkz3PXnvQOxopJJ5h+7txn5T1qFZ5JRIcBQDgFh1rPNzMIAQFPJOc/rST5aLLv8xHbp/+uiw0i7I7xnapDknLN0A/KqzyKisUKgNznuapvcfJGobOOhqKWfAKg4qkgsTiQLISwG4AcEZoklYxDbgd8j+VUUchwTwO9SNISVJwR2qrAx0s+AAeD0GKKqyODwQM9jRVJEszQ2DyBUinkYNQbsnmlVuR6jkV2NHgQnYsqfxoDd+30qJWyOozQDwee1ZtHVGZLxjmhT+Y6UwHNLnBBOKVjVT6kmRk9jSxuF46imbuvQ00e1Kxqpk4YEnGakVsZ6EGqwOQRTs8cdaTRqpXJ84yRnnqKcJABjnjtUG4njgjtQXBOD1PSpsWmWC2DkDIoG3BAODUBbBwPxFAfPpmlYq5bUvEnPOTnr2qVXhZMMgBHT1qkGKj/OaVJAh9R6+lS0O5rWsrRt5qB5FHysjHGae18qT7zETx1A2sKoJJ8owfmJA6VIXccMOnQDt+NTYaRpQO8nzK4cH72/j8aQXcoGNiqRyNxyuPaqsZJQCMKMj5ge/+FNfYimN1ZSDyQalJDJV1MJKdy89Bt5BPvVhrjdEshJQZ6jpWdKueURGPTIpQxXkyBQQMKPp3p8qG2nsaLXLbsFsqAMY+8Pz60JPGzhvPLbjghj7cY9qopsK5G1TjkDNOY4A3Iqk9GBosZtF6N5nuFyIgnRSe/wBaQ3axuRMhxnqo6/WqKGcuNxWSMdcCrESSuzYwVJ5A60WQiyJhjfAqdMHJwB70q3MaDfJHk5JyBWcwMdzkFYx0yPWle4Zgwd1Yg46Y/KjlGaUd6ikbAsm4dA2Kd9pgLAShkcjAJGCB6VkyTMMj5So5yMZFC3zGLYUO0DjIzg+tHKM1mmeOYEOXgbjDcDNSNcoMtGVLdwTx+FYn2hjkFIjjnIzxUe47chVHY8UuUe5q/bwSpBMTL13dPzqUXCupCTBmIxz3+tYwneIkls5OAAvSo/ORW3INj9BzzRyBbsaMlwiqFmLBgeCBxTDctIBmbGOxHT3rOld3ZBIcp1BJ704TbVw3QdABT5Rk8sisepI6YqIygR4ZSWHIJPNQy4yW2kAjmo2YdFyrdapRAstMxADqxHQAH9Ke00kijLEADuaz2baCCxJPtQHJzk5x2p8oGm9wQNrqCB3BqLzdoIgBDetUJGX15p32ghNo4/SlyAmWzK5UDauBwOajMhC5z6jGarFweMkAU0vhSAevtT5R3JlYMehGO/rSF8EknI7mod3AIIBPAFIzZ61XKS5EhIDZJzQJCSSDUTNxjAHHFN3DpjinykuQ8sMcGiombHHGKKqxk6linmlz9abmjPIrpZ4I8NShv5VFnB60m7FKxak0T7sHg/rT/M9aq5pQ1LlNI1Wi3vBHTikL9xVYPzSh89KnlNFWuWd+Dg9aduGfaqwbt396C2PpQ4mirWLe/wB+9G/nr9Krh8ClZuOtTym6rFjdke45oDKeCMmqxYHvTt4xU8prGsiwH4PUqadvOOACKq7hg80objg4FJxNVNFsSMPYVPCxHKsQfQniqKOR3B6Hmnh8n3FS4miZfdyUwSD7g9KejOV+Q7lIzhx/KqKy5wRxUonQKCBtx0IqeUq5LuYjC5XIySDx9PanxzBRtZSCODnnFVzKPLzuAz3HT8RQkgA+UA8c9uaLCLMsoZskcAcFuv8A9ekeVlUB8bTyRuqo0hAwuBkdDTfMBXoq4Pp1o5QLzyAZKnqO1MjuJYsjPyfX1qt5mfvAZ6hhTGbKnBJp8oGpJIGjBRgzdDk1EXDY5BPXPf6VnAnkAnrTllABzjPvRyi2LRm5yRwOvvQvUMCduM4zVYPkg/oaR5N4G7Ax3FLlHcs5w3CZGOvX8RS+bhfn3EeuetVAxxw2R7ikBbZndzTsFy15oXJXA9QeM0xpg33lDfQVXdySN2PwpN5zgYAp8oXJWcbhg49aRpMrtzjvUJkbgAimlsjqB7U1EOYsGZh0c/QGmtKXwWPtmoGPqc0hPsKaiLnJ2mP8X0+tI7o38ODVcnr0FGeDyc0+UzdToTZxjbginZwD1B5xVYt7/jQW6570covaosF8Drke1NZsDA6//rqEse/SgseRRyi9skTM3PXj2pCw5zURfNNd8+lUomUqyJtwpC3HpUJb/IpCeec0+UxlWuSlwPU0VCzc+ntRTUTCVXUSk/8ArUUVqzjEpD0oopAhBSUUUDClH3qKKAQo6UvaiikWh4+9QOtFFJm0dwb7tKv9KKKk1juKOppy0UUmbR3DP86mi6H8KKKlnRATJwOTS5PHPpRRUmxKo+Zvxpr8R8UUUDFH3KevJb2oopAyOQDzHGOP/wBdJIMMhHBOaKKoGDdD/nvTX+9+P+NFFCExH4Jx6UIefwoooJ6iv0P1NNkJweaKKBsYSfU0EkLwe9FFMzYhJyOaAeR9KKKZAMefwpP4RRRQTIbk560h60UVSMpgtOBPPNFFJiQh6mmt0oopkyAngUg6miimYvcQ9aO35UUUzNjT0oooqjM//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_49_22303=[""].join("\n");
var outline_f21_49_22303=null;
